

1 **Assessment of upper limb movement disorders using wearable sensors during**
2 **functional tasks: a systematic review**

3 **Inti Vanmechelen*¹, Helga Haberfehlner^{1,2}, Joni De Vleeschhauwer³, Ellen Van Wonterghem¹, Hilde**
4 **Feys³, Kaat Desloovere⁴, Jean-Marie Aerts⁵, Elegast Monbaliu¹**

5 ¹ Research Group for Neurorehabilitation (eNRGy), KU Leuven Bruges, Department of Rehabilitation
6 Sciences, Bruges, Belgium

7 ² Amsterdam Movement Sciences, Amsterdam UMC, Department of Rehabilitation Medicine, Amsterdam,
8 The Netherlands

9 ³ Research Group for Neurorehabilitation (eNRGy), KU Leuven, Department of Rehabilitation Sciences,
10 Leuven, Belgium

11 ⁴ Research Group for Neurorehabilitation (eNRGy), KU Leuven, Department of Rehabilitation Sciences,
12 Pellenberg, Belgium

13 ⁵ Division of Animal and Human Health Engineering , KU Leuven, Department of Biosystems, Measure,
14 Model and Manage Bioresponse (M3-BIORES), Leuven, Belgium

15 *** Correspondence:**
16 Corresponding Author: inti.vanmechelen@kuleuven.be

17 **Keywords: (Min.5-Max. 8)**

18 Inertial Measurement Units (IMUs); Upper Extremity; Parkinson's Disease; Tremor; Stroke;
19 Dystonia; Ataxia; Huntington's disease

20

21 Number of words: 8307

22 Number of tables: 3

23 Number of figures: 5

24

25

26

27

28

29

30

31 **Abstract**

32 Background: Studies aiming to objectively quantify upper limb movement disorders during
33 functional tasks using wearable sensors have recently increased, but there is a wide variety in
34 described measurement and analyzing methods, hampering standardization of methods in research
35 and clinics. Therefore, the primary objective of this review was to provide an overview of sensor set-
36 up and type, included tasks, sensor features and methods used to quantify movement disorders during
37 upper limb tasks in multiple pathological populations. The secondary objective was to select the most
38 sensitive sensor features for symptom detection and quantification and discuss application of the
39 proposed methods in clinical practice.

40 Methods: A literature search using Scopus, Web of Science, and PubMed was performed. Articles
41 needed to meet following criteria: (1) participants were adults/children with a neurological disease,
42 (2) (at least) one sensor was placed on the upper limb for evaluation of movement disorders during
43 functional tasks, (3) comparisons between: groups with/without movement disorders, sensor features
44 before/after intervention, or sensor features with a clinical scale for assessment of the movement
45 disorder. (4) Outcome measures included sensor features from acceleration/angular velocity signals.

46 Results: A total of 101 articles were included, of which 56 researched Parkinson's Disease. Wrist(s),
47 hand and index finger were the most popular sensor locations. The most frequent tasks for
48 assessment were: finger tapping, wrist pro/supination, keeping the arms extended in front of the body
49 and finger-to-nose. The most frequently calculated sensor features were mean, standard deviation,
50 root-mean-square, ranges, skewness, kurtosis and entropy of acceleration and/or angular velocity, in
51 combination with dominant frequencies and power of acceleration signals. Examples of clinical
52 applications were automatization of a clinical scale or discrimination between a patient/control group
53 or different patient groups.

54 Conclusion: Current overview can support clinicians and researchers to select the most sensitive
55 pathology-dependent sensor features and measurement methodologies for detection and
56 quantification of upper limb movement disorders and for the objective evaluations of treatment
57 effects. The insights from Parkinson's Disease studies can accelerate the development of wearable
58 sensors protocols in the remaining pathologies, provided that there is sufficient attention for the
59 standardisation of protocols, tasks, feasibility and data analysis methods.

60

61

62

63

64

65

66

67

68 1 Introduction

69 The execution of functional tasks requires fine-tuned coordination of multiple upper limb joints,
70 which is often disturbed in individuals with movement disorders [1-3]. Movement disorders can be
71 defined as “a neurological syndrome in which there is either an excess of movement or a paucity of
72 voluntary and automatic movements” and are the consequence of lesions in the basal ganglia,
73 cerebellum or thalamus brain regions. They are present in a variety of neurological diseases and can
74 occur in every phase of the life cycle [4]. Prevalence of movement disorders increases with age, up to
75 28% in a general population over 50 years old and 50% for individuals over 80 years old [5]. In
76 several neurologic diseases, movement disorders belong to the main symptom of the disease. In
77 childhood, neurologic movement disorders are most often associated with a diagnosis of dyskinetic
78 cerebral palsy (CP) or with primary dystonias (i.e., inherited or idiopathic dystonias) with a
79 prevalence of 25-50/100 000 and 15-30/100 000, respectively [6-8]. In individuals over the age of 50
80 years, the prevalence of primary dystonia increases to 732/100 000 [9]. In the elderly, the most
81 prevalent condition causing movement disorders is Parkinson’s disease (PD), reporting a prevalence
82 of 1-2 per 1000 adults [10].

83 Movement disorders lead to slower movement execution, increased movement variability and a
84 decrease in functionality [11-15]. Both in early-onset and late-onset movement disorders, accurate
85 evaluation is indispensable for the follow-up of the disease course – especially in progressive
86 movement disorders – and to evaluate and optimize the effect of treatment strategies. Currently, the
87 effect of an intervention program on upper limb function or the presence and/or severity of
88 movement disorders is mostly evaluated using clinical assessment scales such as functional scales
89 and movement disorder severity scales [16-18]. The Unified Parkinson’s Disease Rating Scale
90 (UPDRS), the Movement Disorders Society revised version of this scale (MDS-UPDRS) and the
91 Hoehn and Yahr scales are currently the most often used assessment scales in PD, whereas the
92 Essential Tremor Rating Assessment Scale is used to rate the severity of essential tremor during nine
93 functional tasks [19-22]. To evaluate the severity of ataxia, the Scale for the Assessment and Rating
94 of Ataxia (SARA) is most often applied [23]. In stroke, the Wolf Motor Function Test (WMFT) and
95 Fugl-Meyer Assessment (FMA) are mainly used to evaluate motor function post-stroke [19, 21, 24-
96 26]. The Action Research Arm Test (ARAT), Box & Block test, Nine Hole Peg Test and Jebsen-
97 Taylor Test evaluate hand function in multiple pathologies, amongst other multiple sclerosis (MS)
98 and stroke, whereas the Monkey Box test was recently developed to evaluate bilateral motor function
99 in Huntington’s Disease (HD) [27-29]. For children with CP, the Melbourne Assessment is a
100 validated measure for upper limb activity [30, 31]. Apart from upper limb activity evaluation scales,
101 the severity of movement disorders such as dystonia can be evaluated with the Burke–Fahn–Marsden
102 Dystonia Rating Scale (BFMDRS) or the Dyskinesia Impairment Scale (DIS) in children and
103 adolescents with dyskinetic CP [32, 33].

104 A common drawback of all abovementioned activity and movement disorder severity assessment
105 scales is that they have to be evaluated by clinicians through the use of standardized guidelines or
106 definitions with respect to task execution or presence/severity of the movement disorder. This clinical
107 judgement induces subjectivity, as not all clinicians may interpret a definition or guideline in exactly
108 the same manner. Moreover, the attribution of scores by a clinician based on video recordings is
109 time-consuming, especially if frequent monitoring is required to evaluate disease progression or the
110 effect of an intervention.

111 In an effort to reduce the subjective aspect in the evaluation of movement disorders, motion analysis
112 has been widely introduced as an alternative to objectify movement disorders, as well as to evaluate

113 the effect of treatment interventions in PD [34, 35], CP [36-38] and stroke [39-41]. While three-
114 dimensional motion analysis is the gold standard in movement analysis, it requires a specially
115 equipped expensive laboratory whereby patients need to visit the hospital or study center for study
116 participation or assessment of rehabilitation.

117 With both the time-consuming aspect of clinical scoring and the location-restricted aspect of three-
118 dimensional motion analysis as main drivers, multiple studies have recently attempted to automate
119 clinical scales with the use of wearable sensors or inertial measurement units (IMUs). These devices
120 are attractive because of their ease-of-use and portability, omitting the necessity for a standardized
121 laboratory which is in particular relevant for long-time follow-up or home-based measures for less
122 mobile patients. IMUs measure linear acceleration and angular velocity of the segment they are
123 placed on, whereas accelerometers measure only acceleration and gyroscopes measure only angular
124 velocity. Specific features derived from acceleration and angular velocity measures can be used to
125 characterize (pathological) movement patterns during multiple tasks or daily life activities. The use
126 of wearable sensors for objective assessment has been previously discussed in PD [42], but this
127 overview focused on all symptoms of PD, consequently providing very little information on specific
128 upper limb tasks. Similarly, Tortelli and colleagues discussed the use of portable digital sensors in
129 HD, whereby the focus was mostly on the assessment of activity and gait [43]. In dyskinetic CP, a
130 recent review discussed instrumented measures for the assessment of dyskinetic CP symptoms, but
131 this scope was not limited to IMUs and therefore less detailed on the topic [44]. While these previous
132 reviews provide much needed insights in the domain of each pathology, an overarching view of
133 sensor protocols and features for the assessment of movement disorders during upper limb tasks
134 could enhance standardisation of data collection. Such standardisation facilitates multi-centre studies
135 and international collaborations and comparison between characteristics of movement disorders
136 between diseases. Therefore, the primary objective of this review was to provide an overview of
137 sensor set-up and type, included tasks, sensor features and methods that are used to evaluate
138 movement disorders during upper limb tasks in multiple pathological populations. The secondary
139 objective was to select the most sensitive sensor features for symptom detection and quantification
140 and describe the application of the proposed methods in clinical practice.

141 **2 Methods**

142 *Search strategy*

143 The full literature search was conducted following the Preferred Reporting Items for Systematic
144 Reviews and Meta-Analyses (PRISMA) guidelines [45]. A literature search using three different
145 databases was performed: Scopus, Web of Science, and PubMed until July 2022. Following terms
146 were used in “all fields”:

147 #1: sensor OR inertial measurement unit; #2: arm OR upper limb; #3: movement disorder

148 Subsequently, all three databases were searched for #1 AND #2 AND #3.

149 *Article screening*

150 Articles (n = 990) retrieved from the literature search were extracted. An overview of the articles
151 retained at each stage of the screening process can be found in the PRISMA flow diagram presented
152 in Figure 1 [45]. Any duplicated articles, retrieved by more than one database, were removed by de-
153 duplication based on congruity in authors, title, and year of publication.

154 Unique articles (n = 903) were screened by I.V. for inclusion according to the criteria below in two
155 consecutive stages: (1) title-abstract; and (2) full-text screening.

156 Articles were screened for inclusion along a set of pre-defined eligibility criteria for (1) the title-
157 abstract and (2) the full-text screening stages. These criteria were designed in line with the
158 PICO/PECO framework [46], which clarifies the review objectives and inclusion criteria across four
159 domains: (P) it was required that the participants were adults or children with a neurological disease
160 subsequently leading to a movement disorder in (but not limited to) the upper limb. (I/E) a minimum
161 of one wearable sensor was placed on the upper limb for the evaluation of movement disorders
162 during the execution of an upper limb task. (C) multiple comparisons were possible: i) a group with
163 movement disorders compared with a healthy group, ii) comparison of sensor features before and
164 after an intervention or iii) comparison of sensor features with scores of a clinical scale. (O) Outcome
165 measures needed to include sensor features derived from acceleration or angular velocity signals.
166 Studies from the same authors who mentioned the exact same features in the same population as a
167 study that was already included were excluded. Additionally, to meet the inclusion criteria, articles
168 were required to be original research containing empirical data. Finally, only articles published after
169 the year 2000 were included.

170 *Data extraction*

171 Relevant information from each included article was extracted in a custom-made Excel based
172 (Microsoft Office, Microsoft, Redmond, WA, USA) data extraction form. Information regarding goal
173 population, sensor type, number of sensors, location of sensor(s), included tasks, sensor features and
174 statistical method was obtained to address objective 1. To address objective 2, the sensitivity and/or
175 responsiveness of the sensor features were extracted for the articles that provided the contribution of
176 individual sensor features. Finally, the clinical application of the proposed method was extracted.

177 **3 Results**

178 *General information*

179 From the 166 full-text articles screened for eligibility, 62 were finally included. Additionally, 39
180 articles were included from citations of screened articles. The full-text articles that were screened but
181 excluded and the reasons for exclusion can be found in Supplementary Material S1.

182 Of the included studies, 56 included adults with PD [11, 47-101], of which 46 assessed one or
183 multiple symptoms of PD and 10 studies specifically focused on Parkinsonian tremor [91-100].
184 Twelve studies included patients with essential tremor [102-113] and 11 included adults post-stroke
185 [15, 28, 114-122], whereas six included adults with MS [123-128]. One study included adults with
186 HD and eight studies included children or adults with ataxia [29, 129-136]. Five studies included
187 children with CP while two studies included children with dystonia and spasticity, respectively [12,
188 13, 137-141] (Figure 2).

189 *Type, number and location of sensors*

190 Table 1 provides an overview of type and number of sensors used, and their respective location for
191 all included studies. From the 101 identified studies, 24 studies used an accelerometer [29, 47-49, 51,
192 53, 54, 56, 63, 89, 91, 94, 96, 104, 111, 115, 116, 119, 120, 127, 134, 138, 140, 142], 13 studies
193 measured motion with a gyroscope or angular sensor [50, 52, 58-61, 64, 73, 79, 105, 108, 110], four
194 studies collected motion data using an orientation sensor, motion sensor or magnetic motion tracker

195 [13, 55, 80, 114], 58 studies used IMUs including an accelerometer and gyroscope [11, 12, 15, 28,
 196 57, 62, 65, 67-72, 74-78, 81-88, 90, 93, 98-101, 106, 107, 109, 112, 113, 117, 118, 121-123, 125,
 197 126, 128, 129, 131-137, 139, 141, 143, 144] and three studies included IMUs but only used the
 198 acceleration signal for further analysis [102, 103, 107], while one study used IMUs but only
 199 processed angular velocity signals [97].

200 The number of sensors ranged from one to 17. Thirty-seven studies used only one sensor, either on
 201 the finger, hand, wrist or forearm [15, 50-52, 59, 61, 63, 68, 69, 72, 75, 79, 84, 89, 91, 94, 96, 97, 99,
 202 100, 104, 106, 108, 109, 112-114, 117, 118, 122-124, 126, 127, 131, 134, 140], while seven studies
 203 used two sensors bilaterally placed on the hand or wrist [60, 66, 78, 81, 82, 133, 137]. Nine studies
 204 used two sensors of which the majority placed one on the thumb and one the index finger [54, 58, 64,
 205 70, 71, 73, 85, 88, 101], while Martinez-Manzara et al. used one sensor on the hand and one on the
 206 finger [67], Samotus et al. and Rahimi et al. put one on the wrist and one on the index finger [95,
 207 111] and Shawen et al. put one on the hand and one on the wrist [86]. In the studies where three
 208 sensors were used, the most frequent locations for PD and tremor were hand, forearm and upper arm
 209 [74, 92, 102, 116], index finger, hand, forearm [105, 110] or index finger, forearm and upper arm
 210 [132, 135]. In children with CP, Newman et al. attached one sensor on the sternum and two on both
 211 upper arms [12] and in HD, Bennasar et al. placed one sensor on the sternum and two on the wrists
 212 [29]. In stroke, Van Meulen et al. fixed one sensor on the wrist, sternum and sacrum [121]. When
 213 four sensor were used, sensor placements were: three fingers and the wrist in PD [83], thumb, index
 214 finger, wrist and upper arm in stroke [119], hand, forearm, upper arm and shoulder in spasticity
 215 [141], hands and forearms [90, 103] and wrists, trunk and head in PD [76]. Four more studies also
 216 included lower limb sensors, where three placed sensors on both wrists and ankles and Zwartjes et al.
 217 included wrist, foot, thigh and sternum [57, 77, 87, 139]. Four studies used five sensors on the upper
 218 limbs, with sensor placement on hand, wrist, upper arm, shoulder and sternum in MS [125, 128],
 219 thumb, index finger, hand, forearm, upper arm and sternum for Di Biase et al. and hand forearm,
 220 upper arm, head and back for Sanger et al. (note that both studies are based on magnetic or
 221 orientation sensors) [13, 80]. Seven studies used six sensors, where the sensor placement was thumb,
 222 index finger, hand, forearm, upper arm and sternum [115, 120]. Two studies placed the sensors on
 223 hands, forearms and upper arms [98, 107], while Krishna et al. used one sensor but subsequently
 224 fixed it on both hands, wrists and ankles, thus including six sensor signals in the analysis [129].
 225 Cheralu et al. placed sensors on the hand, scapula, thorax, sacrum, head and shank, while Tsipouras
 226 et al. attached sensors bilaterally on ankles and wrists and one the waist and chest [55, 62]. Repnik et
 227 al. used seven sensors on the hands, wrists, upper arms and sternum and Hof et al. and Keijsers et al.
 228 placed the sensors on the wrists, upper arms, trunk and upper legs [28, 47, 48]. Five studies used
 229 eight sensors. Delrobaei et al. placed the sensors on the hands, wrists, upper arms, and shoulders and
 230 Bonato et al. on the forearms, upper arms, thighs, right shin and sternum [49, 65]. Patel et al. and
 231 Cole and colleagues attached the sensors on the forearms, upper arms, shins and upper legs [53, 56],
 232 whereas in ataxia, Kashyap and colleagues placed sensors on the index finger, hand, wrist, foot,
 233 sternum, back and ankles [136]. Finally, Van den Noort et al. used 11 sensors, all located on the hand
 234 and fingers [11] and Delrobaei and colleagues used 17 sensors placed on the hands, wrists, upper
 235 arms, clavicle's, sternum, head, pelvis, upper and lower legs and feet [93]. In one study, the number
 236 of sensors was not specified [138].

237 *Upper limb tasks*

238 The upper limb tasks occurring in more than one study are presented in Figure 3. Wrist
 239 pro/supination was included in 25 studies [11, 50, 52, 53, 58, 60, 65, 69, 72-74, 76, 78-83, 86, 88,
 240 101, 106, 129, 132, 144] whereas finger tapping was included in 24 studies [11, 49, 51, 54, 58, 59,

241 61, 64, 67, 69, 71-73, 79, 80, 83, 85, 88, 101, 131, 136, 144-146]. Keeping arms in front of the body
 242 was included in 23 studies [52, 66, 91, 93, 95, 97-100, 103-105, 107-113, 125-128], as well as finger-
 243 to-nose [13, 53, 76, 86, 91, 97-99, 104, 108, 112, 113, 124-129, 132, 133, 135, 136, 144]. Drinking
 244 from a can/cup was included in 13 studies [47, 48, 52, 57, 62, 76, 86, 87, 107, 113, 117, 120, 141],
 245 and opening/closing of the hand in seven studies [11, 58, 69, 71, 83, 88, 101] as well as
 246 writing/drawing [52, 76, 77, 86, 102, 106, 113]. Eating was included in six studies [48, 52, 68, 77,
 247 84, 87] as well as pouring water [76, 86, 108, 113, 126, 127] whereas reaching/grasping objects was
 248 included in five studies [117, 121, 126, 127, 137]. Teeth brushing was included in four studies [52,
 249 68, 77, 84] as well as putting clothes on/off [47, 48, 77, 87]. In stroke, the Wolf Motor Function test
 250 or parts of this clinical scale were included four times [115, 118-120] and four studies measured
 251 activities in an unrestricted home environment [63, 89, 134, 139]. Combing hair was included in
 252 three studies [52, 77, 87] as well as typing and folding laundry [76, 77, 86] and forwards and
 253 sideways reaching [12, 114, 116]. Tasks from the ARAT were included in two studies [28, 123].
 254 Finally, following tasks were included once: the monkey box test [29], the box and block test [90],
 255 holding a weight with the wrist [96], wrist extension [75], wrist ab/adduction, flexion/extension,
 256 elbow flexion/extension and pro/supination [92], and following a bent wire shape with a wand loop
 257 [104]. One study included wrist supination/flexion, hand behind back and wrist flexion/pronation
 258 [15]. In CP, one study included outwards reaching [13], one included the drinking test, the bean bag
 259 test and the nine hole peg test [141] while Strohrmann et al. included turn around cards, pick up small
 260 objects, stack dominos, open & close & bottle, use a key, and the nine-hole peg test [137]. Kim et al.
 261 included the Jebsen Taylor Hand Function Test, the Quality of Upper Extremity Skills Test and the
 262 Box and Blocks Test [138].

263 *Sensor features*

264 Table 2 provides an overview of the calculated sensor features in the time-and frequency domain, as
 265 well as a formula or feature description when given in the original study. As an easy and
 266 straightforward feature, execution time was often calculated for the upper limb tasks for stroke [15,
 267 28, 117], MS [123], PD [11, 49, 54, 71, 75, 80], tremor [102, 144], CP [137] and ataxia [132, 134].
 268 The frequency of movements was popular in multiple studies in PD, mostly in repetitive tasks such
 269 as finger tapping and pro/supination [64, 83].

270 For the studies where both acceleration and angular velocity signals were collected, both mean and
 271 standard deviation (STD) were often calculated [62, 78, 86, 87, 90, 118, 129, 139], as well as root-
 272 mean-square (RMS) values [11, 86, 89, 129, 139]. Additionally, mean and RMS or STD of
 273 acceleration and angular velocity separately were used in studies where one of the signals was
 274 available [29, 50, 52, 54, 57, 63, 64, 66, 71, 74, 82, 83, 85, 89, 96, 104, 105, 108, 110, 111, 115, 119,
 275 120, 132-134, 137], as well as median angular velocity in one study [82]. Maximal linear velocity
 276 was additionally often used as key feature, mostly by integration of the acceleration signal [51, 54,
 277 115]. The range of angular displacement or range of motion was only used in studies in PD [58-60,
 278 69, 79, 83], mainly to assess hypokinesia. The range of acceleration and angular velocity was
 279 included in PD [53, 54, 75, 80, 86, 89, 122], tremor [133] and CP [12, 137], as well as the inter-
 280 quartile range for PD [82, 89]. The range of jerk and angular acceleration was used in one study in
 281 PD [72].

282 Peak-to-peak and magnitude of angular velocity were additionally used in PD [73, 77, 80, 87],
 283 whereas Repnik and colleagues calculated a rotational jerk index for angular velocity values to
 284 evaluate hand rotation in stroke [28]. Finally, a study in PD used the square root of the sum of
 285 squares of jerk signals and named this feature 'segment velocity' [48].

286 As basis statistical features, kurtosis and skewness were popular in PD [66, 76, 78, 86, 87, 118], but
287 not in other populations apart from one ataxia study [134]. With respect to signal dynamics, multiple
288 forms of entropy were used, most commonly sample entropy and approximate entropy in PD [53, 55,
289 62, 66, 70, 76, 86], stroke [120] and ataxia [136] and Shannon entropy and permutation entropy in
290 PD [87], dyskinetic CP [139] and HD [29]. Fuzzy entropy was additionally calculated in two ataxia
291 studies [131, 144]. Apart from entropy, the Gini index and Lyapunov exponent were additionally
292 used as a measure of signal complexity in PD [87], ataxia [131] and HD [29]. The same HD study
293 additionally used recurrence rate, determinism and average diagonal line to evaluate signal dynamics
294 [29].

295 For signal smoothness, RMS of jerk was often used as a straightforward measure in PD [118] and
296 stroke [115, 116], as well as a jerk metric for which multiple definitions were given, mostly RMS
297 jerk normalized over time/peak velocity or mean jerk [12, 15, 76, 89, 90, 115, 123, 139, 141].
298 Additionally, smoothness measures were also described as the difference between movement
299 accelerometer readings and smoothed readings, number of movement units or number of speed peaks
300 [114, 122, 141].

301 Coefficient of variation was often used as a measure of variability or rhythm for different signals
302 such as excursion angle [58, 69, 79, 101], (angular) velocity [58, 64, 79], amplitude [64, 71] and
303 movement frequency [64, 83, 144], while two studies in PD defined ‘rhythm’ via the STD of
304 intervals of a finger tapping movement [51] and any sequence of regularly occurring events [67].
305 Finally, a stroke study defined variability as the RMS error between a reference trial and a warped
306 trial [117]. Considering the geometrical structure of a non-linear time-series, Newman et al. included
307 Higuchi’s fractional dimension in children with CP [12].

308 With respect to orientation and rotational information, correlation between the different axes of the
309 accelerometer or gyroscope was often included as a feature in PD [76, 86, 89, 99], HD [29] and
310 stroke [115]. Additionally, the peak of the normalized cross-correlation from pairs of acceleration
311 time series and the lag of first peak in autocorrelation acceleration were included in two PD studies
312 [53, 56]. Concerning trajectories and travelled distances, multiple studies used different definitions
313 for this feature. 3D hand trajectory and length of 3D trajectory [121] and path-length ratio were used
314 in stroke [114], while the index of curvature (deviation from a straight line) was used in dyskinetic
315 CP [13]. Elevation angle was included in a CP study, while in stroke, the similarity of hand
316 trajectories was used [12, 28]. Two studies in patients with ataxia used mean and standard deviation
317 of Euclidian distance from the mean trajectory and curved and straight-line similarity analysis [132,
318 135]. In PD, Heldman et al. used a bradykinesia index, based on variability in time and amplitude of
319 task execution whereas Tamas et al. and Garza-Rodriguez and colleagues quantified hypokinesia
320 using velocity decrement, which is defined as a decrease in velocity between subsequent data parts
321 [69, 82].

322 In the frequency-domain, the dominant frequency component of acceleration/angular velocity or both
323 was most often used [47, 53, 84, 87, 91, 94, 97-99, 104, 112, 115, 126, 127, 129], while only three
324 studies included the second dominant frequency or dominant frequency of jerk [87, 115, 136].
325 Energy in the frequency spectrum was often included in multiple populations, both for the
326 acceleration signal [49, 53, 56, 66, 115, 119, 120], angular velocity signal [100] or both [15, 62, 129].
327 One PD study additionally included amplitude and dominant frequency of modulations associated
328 with the acceleration signal as well as fractal dimension [49], while one HD study included the
329 average magnitude of the first five Short-Term-Fourier-Transfer components [29]. Apart from the
330 frequency, power in specific frequency bands was a popular feature in multiple populations,

331 including spectral power [68, 77, 84, 87, 102, 113, 118, 140], peak power [59, 60, 73, 87, 94], total
 332 power [59, 60, 73, 80, 99, 102, 104, 105, 110, 125, 134], mean power [63] and band power [139].
 333 Considering entropy in the frequency domain, spectral entropy was used in two PD studies [62, 87]
 334 and one ataxia study [131], as well as component entropy in HD [29]. Spectral Arc Length was used
 335 as a measure of smoothness in two PD studies and one CP study [12, 73, 80]. For tremor studies,
 336 tremor frequency and tremor amplitude [109] were included as well as multiple specific tremor
 337 indices: Carpinella et al. defined the tremor index as the ratio of tremor (defined by peaks in the
 338 frequency spectrum) and the norm of angular velocity [124]. Western et al. defined average tremor
 339 amplitude as the product of frequency bins, sampling period and the signal's power spectral density
 340 [128], whereas Benito-Leon et al. and McGurrin et al. used the mean logarithmic tremor power and
 341 tremor rotational amplitude/amplitude respectively, based on identified peaks in the power spectrum
 342 [103, 106].

343 *Statistical method used*

344 Figure 4 gives a representation of the statistical methods used in the included studies. Forty-five
 345 studies included between- or within-group comparisons using statistical tests [12, 13, 28, 47, 51, 55,
 346 58-60, 62-65, 69, 70, 73, 75, 79, 80, 85, 89, 90, 92-94, 96-98, 102, 104, 105, 109, 111, 114, 117, 123,
 347 124, 131, 134, 137, 140-142, 144], mainly parametric and non-parametric ANOVA and parametric
 348 and non-parametric t-tests, whereas 43 studies used machine learning [15, 29, 48, 49, 53, 55-57, 62,
 349 63, 66, 67, 72, 74-78, 81-84, 86-89, 100, 102, 112, 113, 115, 118-120, 122, 126, 129, 132, 133, 135,
 350 136, 139, 144]. Twenty-five studies evaluated correlation of sensor features with clinical scales [12,
 351 28, 51, 52, 54, 59, 60, 65, 70, 71, 80, 93, 103, 106-108, 110, 127-129, 131, 133, 134, 138, 144],
 352 whereas nine studies used regression analysis for a similar purpose [13, 54, 101, 102, 109, 116, 121,
 353 133, 137]. Finally, five studies used only descriptive statistics or observation without hypothesis
 354 testing [11, 68, 91, 99, 125] and two studies evaluated ROC curves [61, 133]. The sum of these
 355 numbers does not add up to 101, because multiple studies used multiple of the abovementioned
 356 methods. Eleven studies used both statistical tests for comparison between groups and correlation
 357 with a clinical scale [12, 28, 59, 60, 65, 70, 71, 80, 93, 131, 134], whereas five studies used statistical
 358 tests and machine learning [55, 62, 63, 75, 89]. Yokoe et al. used both logistic regression and
 359 correlation with a clinical scale in PD [54]. In patients with ataxia, Tran et al. used statistical tests,
 360 correlation with a clinical scale and machine learning [144] and Oubre et al. used statistical tests,
 361 regression, correlation with a clinical scale and machine learning [133]. In participants with essential
 362 tremor, Ali et al. used statistical tests, regression analysis and machine learning [102] and Sprdlik et
 363 al. used statistical tests, ROC curves and regression analysis [109]. In CP, Sanger et al. used both
 364 regression analysis and ANOVA/t-tests [13], and Strohrmann et al. used a t-test, to subsequently
 365 continue with a linear regression for the features that were significantly different between groups
 366 [137].

367 *Sensitivity and/or responsiveness of most prevalent sensor features*

368 Table 3 provides an overview of the features included by more than five articles, the number of
 369 articles reporting sensitivity of the specific feature and the number of articles that identified a
 370 significant difference between groups, severity levels or pre/post intervention.

371 RMS of angular velocity was reported in 18 studies, with sensitivity results for 11 studies. In PD,
 372 Van den Noort et al. found significantly higher RMS values for ON vs OFF dopaminergic
 373 medication, while Summa et al. did not find a significant difference between medication states [11,
 374 73]. Espay et al. found 25% improvement in RMS values after dopaminergic medication in PD

375 patients [58]. Kwon et al. and Luksys et al. found significant higher RMS angular velocity values for
 376 PD patients in comparison with controls, whereas two studies found a correlation of -0.78 between
 377 RMS angular velocity and clinical scores of the UPDRS [59, 60, 79, 98]. Additionally, Heldman et
 378 al. found a correlation of -0.78 between RMS angular velocity values and the modified bradykinesia
 379 rating scale [101] and Salarian et al. found good correlation between RMS angular velocity values
 380 and the UPDRS bradykinesia subscore, as well as good correlation between RMS angular velocity of
 381 the roll axis and the tremor subscore of the UPDRS [52]. In patients with tremor, spearman
 382 correlation between RMS angular velocity and tremor severity scores ranged from 0.19 (finger-to-
 383 nose) to 0.73 (keeping arms extended in front of the body) for Lopez-Bianco et al. [108] and between
 384 0.41 and 0.70 for Kwon et al. [110], whereas Heo et al. found lower RMS angular velocity values
 385 after electrical stimulation [105].

386 Seventeen studies reported mean acceleration as a feature, but only two PD studies and one ataxia
 387 study discussed its sensitivity. Romano et al. found lower mean acceleration for PD patients in
 388 comparison with the control group, while Zwartjes et al. did not find significant differences between
 389 ON and OFF stimulation states of deep brain stimulation [57, 90]. In patients with Ataxia, Samotus et
 390 al. found lower mean acceleration after botulinum-toxin-A injections [111]. Execution time was
 391 included in 17 studies, with reported sensitivity for 11 studies. Execution time significantly differed
 392 between different severity levels [28] and between healthy controls and patients with stroke [28, 117]
 393 and MS [123, 124] and between the paretic and non-paretic arm in children with unilateral CP [12].
 394 Execution time was significantly longer for PD patients in comparison with healthy controls [75, 80]
 395 and for patients with multiple system atrophy of parkinsonian type and progressive supranuclear
 396 palsy in comparison with healthy controls [71]. Third, execution time was significantly different
 397 between the ON and OFF medication state in PD patients [11]. In CP, execution time was one of the
 398 three features to best estimate upper limb performance in a regression analysis [137].

399 The dominant frequency domain was included in 15 studies, but only Hoff et al. reported individual
 400 contributions of this feature, reporting that amplitude in 1-4Hz and 4-8Hz frequency bands correlated
 401 with the modified Abnormal Involuntary Movement Scale [47]. Peak power was included in 12
 402 studies, of which six discussed its individual sensitivity. Jun et al. reported a good correlation
 403 between peak power and clinical bradykinesia scores and Kim et al. reported decreasing peak powers
 404 with increasing UPDRS scales steps [59, 60], while Makabe et al. reported increasing peak powers
 405 with increasing severity stages of the Hoehn and Yahr scale [94]. Similarly, Summa et al. reported
 406 increases in peak power in ON vs OFF medication state [73]. In essential tremor, Heo et al. reported
 407 higher peak power after electrical stimulation [105] and Kwon et al. reported high correlation
 408 between peak power and tremor severity scores [110].

409 Sample entropy was included in 11 studies, but only two PD studies reported its sensitivity. Chelaru
 410 et al. found significantly higher entropy for dyskinetic PD patients in comparison with non-dyskinetic
 411 PD patients, as well as Liu et al. who found a significant difference between PD patients and healthy
 412 controls and good correlation with UPDRS scores [55, 70]. RMS of angular displacement was
 413 included in 11 studies, of which ten reported sensitivity. Tamas et al. found significant differences in
 414 RMS amplitude before and after subthalamic stimulation and Espay et al. found significant
 415 differences between ON and OFF medication state in PD [58, 69]. Kwon et al. found significantly
 416 lower RMS amplitudes for PD patients in comparison with controls and Jun et al. found decreasing
 417 angular displacement with increasing bradykinesia scores, but this was based on visual observation
 418 [60, 79]. Chan et al. found higher values for angular displacement for patients with PD with tremor in
 419 comparison with essential tremor [92]. Kim et al. additionally found a significant difference between
 420 PD patients and controls [59], whereas Heldman et al. found a correlation of -0.81 between RMS

421 excursion angle and clinical scores [101]. Delrobaei et al. found a higher tremor severity score
 422 (which was composed of the RMS values of angular velocity) for tremor-dominant PD patients in
 423 comparison with non-tremor dominant PD patients and good correlation between tremor severity
 424 score and UPDRS scores [93]. In essential tremor, Kwon et al. and Chan et al. found correlations
 425 ranging from 0.29-0.66 and 0.80-0.93 respectively, between RMS angular displacement and tremor
 426 severity scores [107, 110]. Energy and STD of acceleration were included in 10 studies, but none
 427 reported sensitivity.

428 RMS of acceleration was included in 10 studies, but only van den Noort et al. discussed its specific
 429 contribution in PD patients, reporting increased RMS acceleration in ON vs OFF medication state
 430 during a finger tapping and opening/closing of the hand task [11]. Mean angular velocity was also
 431 included in 10 studies with six of them reporting sensitivity. In PD, three studies found lower mean
 432 angular velocity for PD patients in comparison with healthy controls [64, 71, 90], whereas one study
 433 additionally identified significant differences between ON/OFF DBS stimulation [52]. Garza-
 434 Rodriguez et al. found lower angular velocity values for PD patients with higher clinical severity
 435 [81]. In patients with ataxia, Oubre et al. found significant differences between patients and healthy
 436 controls [133].

437 Jerk metrics were calculated in nine studies with five reporting on its sensitivity. Romano et al. used
 438 the dimensionless jerk index as a jerk metric and found a significant difference between PD patients
 439 and healthy controls, while Habets et al. did not find a significant difference between ON and OFF
 440 medication state in PD patients [89, 90]. Carpinella et al. found a significantly higher jerk measure
 441 for patients with MS in comparison with healthy controls and a negative correlation between the jerk
 442 measure and ARAT score ($r = -0.90$) [123]. In children with unilateral CP, Newman and colleagues
 443 found a significantly higher normalised jerk index for the paretic arm in comparison with the non-
 444 paretic arm, but no correlation with the Melbourne Assessment Scale [12]. In children with
 445 spasticity, the normalized jerk score improved significantly after botulinum-toxin A injections [141].

446 Coefficient of variation (CoV) was included in eight studies, where CoV of time and amplitude was
 447 mostly calculated to evaluate bradykinesia. Djuric-Jovicic and colleagues found significant
 448 differences between PD patients and healthy controls for both CoV of time and amplitude, whereas
 449 Lee et al. found significant differences for CoV of speed, amplitude and frequency between PD
 450 patients and controls [64, 71]. Kwon et al. additionally found significant differences between PD
 451 patients and controls for the CoV of angles and velocity [79]. Tamas et al. found that the coefficient
 452 of variation – also called ‘rhythm’ – improved significantly after bilateral and contralateral
 453 subthalamic stimulation, whereas Espay et al. found significant differences between ON and OFF
 454 medication state for CoV in PD patients [58, 69].

455 Spectral power was used in seven studies of which four reported sensitivity. Bravo et al. compared
 456 power spectral density (PSD) plots between PD patients and healthy controls and found both higher
 457 and lower PSD amplitude for PD patients in comparison with healthy controls, depending on the
 458 individual [68]. In patients with dystonia, Legros et al. found a decrease of the area under the
 459 spectrum curve after deep brain stimulation surgery [140]. Ali et al. found higher PSD ratios for
 460 patients with essential tremor in comparison with healthy controls [102], whereas Heldman et al.
 461 found correlations from 0.77-0.83 between the logarithm of peak power and the UPDRS scores
 462 [113]. The range of acceleration was additionally calculated in seven articles, but only two articles
 463 reported its sensitivity. Rabelo et al. found a significantly higher acceleration range for healthy
 464 controls in comparison with PD patients, while Habets et al. did not find a significant difference
 465 between ON and OFF medication state in PD patients [75, 89]. Approximate entropy was also

466 included in seven studies, but only two PD studies included its sensitivity, where Liu et al. and
 467 Luksys et al. found significant differences between PD patients and a control group [70, 98].

468 Range of angular displacement was calculated in six studies, but only four discussed its sensitivity.
 469 Djuric et al. reported a higher range for healthy controls in comparison with PD patients, whereas van
 470 den Noort et al. reported lower displacement in the ON vs OFF medication state and improved
 471 amplitude in the ON compared to OFF state [11, 71]. Romano et al. found significant differences
 472 between PD patients and healthy controls for wrist flexion and shoulder movements and Salarian et
 473 al. found significantly lower angular displacements at the level of the wrist for PD patients compared
 474 to healthy controls [52, 90]. Energy of acceleration in the frequency domain and STD of acceleration
 475 were included in 11 articles, but all of them included these features as part of a feature set for
 476 machine learning, without discussing its individual contribution.

477 Mean acceleration and angular velocity were included in six studies, but only Romano et al. found
 478 significantly lower mean acceleration and angular velocity in PD patients in comparison with healthy
 479 controls [90]. Correlation between axes was included in six studies, but only Zhu et al. reported no
 480 significant differences in correlations when comparing PD patients in ON and OFF medication state
 481 [99]. Kurtosis and skewness were additionally included in six studies, but none of them reported the
 482 contribution of the individual features.

483 *Clinical application*

484 Figure 5 presents an overview of the clinical application of the included studies. Fifty-two studies
 485 used sensor features for the automatization of a clinical scale [15, 29, 49, 51-54, 56, 57, 59, 60, 63,
 486 65, 67, 72, 76-78, 81-84, 86-88, 93, 100, 101, 103, 106-108, 110, 112, 113, 115, 116, 118-123, 126-
 487 129, 131, 133, 137-139]. Sixteen studies used sensor features to evaluate the effect of an intervention
 488 [47, 48, 50, 55, 58, 68, 69, 74, 89, 99, 104, 105, 111, 140-142], whereas 35 studies used the obtained
 489 features to discriminate between patients and controls or between different patient groups [11-13, 28,
 490 61, 62, 64-66, 70-73, 75, 79, 80, 85, 90-94, 96-98, 102, 109, 117, 124, 125, 132, 134-136, 144]. Four
 491 studies subsequently discriminated between different severity levels [28, 65, 72, 114]. Again, there
 492 was some overlap in clinical applications: Delrobaei et al., Spasojevic et al. and Repnik et al.
 493 compared control and patient groups as well as severity levels within the patient group, while also
 494 correlating sensor features with a clinical scale [28, 65, 72]. Kamper et al. compared a patient and
 495 control group but also compared severity levels separately [114].

496 **4 Discussion**

497 The primary objective of this systematic review was to provide an overview of sensor set-up and
 498 type, included tasks, sensor features and statistical methods that are used to evaluate movement
 499 disorders during upper limb tasks in multiple pathological populations. We identified 101 studies in
 500 eight pathological conditions using wearable sensors placed on the upper limb during upper limb
 501 tasks and including at least one sensor feature based on linear acceleration or angular velocity. Of all
 502 included studies, 55% were studies in PD, 12% were studies with essential tremor patients, 11% were
 503 studies in stroke patients, 8% were studies in adults or children with ataxia, 6% were studies
 504 including participants with MS and 5% included children with CP. Adults with HD and spasticity and
 505 dystonia in children represented only 1% of the included studies. When comparing these numbers
 506 with the prevalence of the abovementioned conditions, an important imbalance emerges. Worldwide,
 507 approximately 101 million people are living post-stroke [147], 25 million people live with essential
 508 tremor [148], 17 million people live with CP [149], 10 million people are estimated to live with PD

509 [150-152], approximately 0.2 to 3 million people live with ataxia, depending on the type [153, 154]
510 and 0.2 to 0.5 million people live with HD, depending on the geographical area [155, 156]. While
511 stroke is much more prevalent than PD or essential tremor, this ratio is not reflected in the number of
512 available studies per condition. More surprisingly, where CP is the most prevalent neurological
513 childhood condition included apart from stroke and essential tremor, its high prevalence does not
514 agree with the number of studies investigating the associated movement disorders using wearable
515 sensors. Current findings thus identify a mayor gap between prevalence of a condition and insights in
516 the related movement disorders. Especially for early-onset conditions such as CP, more insights in
517 the disturbed movement patterns from an early age could benefit targeted therapy and long-term
518 treatment management.

519 The abundance of included PD studies reflects its more advanced state-of-the-art assessment in
520 comparison with other pathological populations. These insights offer opportunities and learning
521 experiences for clinicians and researchers aiming to bridge the gap between technology and clinical
522 measures in the quantitative evaluation of movement disorders. Although wide-spread in research,
523 the clinical implementation of IMU-based analysis of movement disorders is lacking in clinical
524 practice in all populations, mainly due to the lack of validation of algorithms in real-world conditions
525 [157].

526 With respect to sensor type, IMUs containing both an accelerometer and gyroscope were most often
527 used, where a time-related trend was clearly visible in the included PD studies: between 2000 and
528 2010, all PD studies included either an accelerometer or a gyroscope, whereas after 2010, IMUs were
529 almost exclusively used. This trend is presumably supported by technological advancements,
530 allowing more sensors in a smaller device with longer battery life combined with more affordable
531 prices for IMUs.

532 Sensor location, number of included sensors and upper limb tasks were separately discussed to
533 provide a comprehensive overview, but conclusions should be drawn on a combination of these
534 settings as they are closely inter-related. E.g., five out of the ten studies that placed one sensor on the
535 index finger included the finger tapping task [51, 59, 61, 69, 113] and of the nine studies who placed
536 a sensor on the thumb and index finger, all included finger tapping [54, 58, 64, 70, 71, 73, 85, 88,
537 101]. When more sensors were used both on the distal and proximal upper limb, tasks ranged from
538 distal upper limb tasks (pro/supination) [65, 74] to a myriad of tasks such as the ARAT [28]. Finally,
539 the four studies that measured activities in a home environment all placed sensors on the wrist,
540 mostly likely due to the high comfort and ease of use of wrist-worn sensors [63, 89, 134, 139].

541 The collection of upper limb tasks included in the selected studies reflects the insight that the choice
542 of upper limb task is heavily dependent on the movement disorder. The high prevalence of finger
543 tapping and wrist pro/supination in the PD studies follows from their presence in the Motor
544 Examination part of the (MDS-)UPDRS [20], whereas the finger-to-nose task and keeping arms
545 extended in front of the body are part of both the (MDS-)UPDRS and the Essential Tremor Rating
546 Assessment Scale [22]. Both tasks are well-suited to quantify decrease and slowness of movements.
547 Since these scales are well implemented in clinical practice, patients are often requested to perform
548 these tasks in the presence of a neurologist. In stroke, the Wolf Motor Function Task was most
549 popular, presumably because this scale is used in daily practice for the evaluation of upper extremity
550 rehabilitation progress. An important notion is that the aetiological differences between PD/tremor on
551 the one hand and CP, stroke and dystonia on the other hand influence the potential of task execution.
552 In CP and stroke, functional ability can be impaired to a level where execution of specific functional
553 tasks is not possible, which requires a very different approach in comparison with PD or tremor,

554 where most tasks can be executed but performance may be impaired. When the level of physical
555 impairment prohibits the execution of specific tasks, one should focus on monitoring of the
556 movement disorders during home-based activities such as powered mobility (e.g. joy-stick steering)
557 or in rest positions in the case of severe CP or stroke [139].

558 The secondary objective was to identify the most sensitive sensor features for symptom detection and
559 quantification and describe the application of the proposed methods in clinical practice. Similar to the
560 requested tasks, the derived sensor features were dependent of the movement disorder under
561 investigation. Mean amplitude, movement/amplitude decrement and RMS, range and IQR of angular
562 displacement were only used in PD studies and are hypothesized to correlate with the definition of
563 hypokinesia (reduction in movement amplitude) in the (MDS-)UPDRS. Range and RMS of angular
564 displacement can detect differences between PD and TD groups and quantify the severity of
565 hypokinesia, implying that these features can be used in clinical practice as simply interpretable
566 triggers of movement reduction. Velocity decrement and peak-to-peak, magnitude, IQR and mean of
567 angular velocity were additionally only used in PD studies and are hypothesized to relate to the
568 bradykinesia (slowing of movement) aspect in the (MDS-)UPDRS, emphasizing their clinical
569 usefulness for early detection of bradykinesia symptoms [81]. Coefficient of variation of both
570 amplitude and velocity as well as rhythm, were included to reflect the interruptions as described in
571 the (MDS-)UPDRS. CoV values are easy to calculate and interpret and showed to be sufficiently
572 sensitive to discriminate between medication and stimulation states in PD patients from both finger-
573 and wrist-worn sensors. This parameter could thus be implemented to evaluate objective intervention
574 effects in large-scale medication or stimulation studies. In essential tremor and studies focusing on
575 tremor in PD patients, occurrence and amplitude of peaks in specific frequency bands as well as
576 power in these frequency bands were most often included, owing to the rhythmical aspect of tremor.
577 However, the selected frequency bands were not always similar. The 4-12Hz frequency band was
578 most often considered as tremor [102, 113], while Heo et al. and Kwon et al. used 3-12Hz [105, 110],
579 Patel et al. used a 3-8Hz band and Schaefer et al. considered 7-12Hz as the tremor frequency [53,
580 96]. Makabe et al. used a range of 8-12Hz and 20-25Hz and Sprdlik et al. used the frequency
581 distribution for highest maxima between 1-15Hz [94, 109]. Lopez-Bianco et al. used a high-pass
582 filter with cut-off 4Hz followed by low-pass filter with cut-off 8Hz [108]. These differences suggest
583 that a solid definition of tremor frequency is required in order to standardize instrumented tremor
584 quantification, to allow comparison of methodologies on a large-scale cross-sectional level and to
585 facilitate data merging and sharing.

586 In pathologies not related to PD or tremor, path length or similarity of hand trajectories were
587 calculated. This was the case in stroke, dyskinetic CP and spasticity, reflecting the importance of the
588 impact of the movement disorder on reaching movements. The frequent use of sensor features such
589 as smoothness and jerk metrics might reflect the effect of the location of the brain lesions on the
590 smooth execution of functional tasks and its impact on daily-life activities in these pathologies.

591 The clinical application of the included studies varied from discrimination of groups to prediction of
592 severity levels and was closely related to the method used to obtain this specific result. With respect
593 to the discrimination of groups, the sensor features sufficiently sensitive to detect differences
594 between a control group and pathological patients could be used for early detection of e.g. PD or MS
595 symptoms, allowing for early intervention and possibly preventing rapid worsening of symptoms. For
596 the prediction of severity levels, all PD studies correlated the sensor features to the (MDS-)UPDRS
597 (or specific sub-items), the AIMS or the Hoehn & Yahr scale. In CP and stroke, sensor features were
598 correlated with the Melbourne Assessment Scale and ARAT, whereas in another CP study, the
599 Jebsen-Taylor Test, the Quality of Upper Extremity Skills Test (QUEST) and the Box and Blocks

600 Test were included. When the clinical application was the (side)effect of intervention, six out of 16
601 studies used sensor features to assess dyskinesia in PD patients, as this is a well-known levodopa-
602 induced motor complication [158]. The (MDS-)UPDRS, Hoehn & Yahr and Essential Tremor Rating
603 Assessment Scale are severity scales, while the Melbourne Assessment Scale, the ARAT, the Jebsen-
604 Taylor Test, the Quality of Upper Extremity Skills Test and the Box and Blocks Test evaluate upper
605 extremity function. In stroke and CP however, the severity of the movement disorder is dependent on
606 the location of the brain lesion, which was not studied in detail in the included studies and has not
607 been fully elucidated to date in most movement disorders. To this end, wearable sensors provide
608 opportunities for detailed exploration of the connection between the location of the brain lesion and
609 the aetiology and severity of movement disorders.

610 IMUs have mostly been used to assess upper limb use and for detection of activity periods in daily
611 life in patients with PD and/or essential tremor [159-161], CP [162-164] or stroke [165], but their
612 application to quantify movement disorders in the upper limb is less extensive. Activity measures
613 mostly focus on the amount of time that acceleration measures exceed a pre-defined threshold (e.g.,
614 Activity Index), which yields information about the quantity of movement, but not about the quality.
615 To facilitate follow-up of intervention or long-term rehabilitation programs, a combined assessment
616 of both movement quantity and quality can provide more insights in both the presence and severity of
617 movement disorders. Ideally, long-term monitoring is executed in a home-environment (i.e., low
618 patient-burden while collecting long-term data), while a contact moment to record pathology-related
619 tasks in a standardized setting could be added to the study protocol since this allows more specific
620 data analysis, e.g., through the presence of video recordings of the performed tasks.

621 The lessons learned from the PD studies in the current review can accelerate the development of
622 wearable sensors protocols in the remaining pathologies, provided that there is sufficient attention for
623 the standardisation of protocols, tasks, feasibility and data analysis methods. These conditions could
624 facilitate reproduction of studies, large-scale multi-centre studies and merging of study results in the
625 near future. The insights provided in current review highlight the potential of wearable sensors for
626 symptom detection and evaluation in CP, stroke, HD, MS and dystonia, but a larger international
627 research focus is urgently required to meet those needs.

628 *Conclusions and future directions*

629 Wearable sensors offer a myriad of opportunities for the quantification of movement disorders in
630 multiple pathologies, but the abundance of available information could threaten its usability. Our
631 findings illustrate that there are a lot of similarities between pathology-related sensor protocols and
632 tasks, but the agreement is yet not sufficient to allow data pooling or international multi-centre
633 studies. For this purpose, higher-level standardisation with respect to task selection and sensor
634 feature extraction per pathology is strongly recommended. Although multiple sensors can provide a
635 lot of information, researchers should think carefully about the balance between information gain and
636 accessibility. One sensor on the index finger for PD or on the wrist for other pathologies could be
637 attached in a non-obstructive way, allowing for better adherence and less missing data due to e.g.,
638 battery loss. Current overview can support clinicians and researchers to select the most sensitive
639 pathology-dependent sensor features and measurement methodologies for detection and
640 quantification of upper limb movement disorders and for the objective evaluations of treatment
641 effects.

642 **Conflict of Interest**

643 *The authors declare that the research was conducted in the absence of any commercial or financial*
644 *relationships that could be construed as a potential conflict of interest.*

645 **5 Author Contributions**

646 **IV:** Conceptualisation, methodology, analysis, data curation, writing-original draft, visualisation.
647 **HH:** Methodology, writing-reviewing and editing. **JDV:** Writing-reviewing and editing. **EVW:**
648 Reviewing and editing. **HF:** Writing-reviewing and editing. **KD:** Writing-reviewing and editing. **J-**
649 **MA:** Writing-reviewing and editing. **EM:** Conceptualisation, writing-reviewing and editing,
650 supervision, project administration, funding acquisition.

651 **6 Funding**

652 IV received an FWO fellowship (Fonds Wetenschappelijk Onderzoek Vlaanderen). The funder had
653 no involvement in study design, collection, analysis and interpretation of data, writing of the report,
654 or in the decision to submit the article for publication.

655 **7 Acknowledgments**

656 The author would like to thank M.N. and S.B. for their help throughout the systematic review
657 process.

658 **8 Supplementary Material**

659 Supplementary Material should be uploaded separately on submission, if there are Supplementary
660 Figures, please include the caption in the same file as the figure. Supplementary Material templates
661 can be found in the Frontiers Word Templates file.

662 Please see the [Supplementary Material section of the Author guidelines](#) for details on the different
663 file types accepted.

664 **9 Data Availability Statement**

665 The data that support the findings of this study are available from the corresponding author upon
666 reasonable request.

667
668
669
670
671

# of sensor(s)	Location of sensor(s)	Type	Goal population
1	Index finger tip	Accelerometer	PD [51, 91, 94, 97]
1	Index finger tip	Gyroscope	PD [59, 61]
1	Index finger	Motion sensor	PD [69]
1	Index finger	Inertial measurement unit	PD [99], tremor [113]
1	Dorsal hand	Angular sensor	PD [50, 79]
1	Dorsal hand	Orientation sensor	Stroke [114]
1	Dorsal hand	Accelerometer	Tremor [104]
1	Wrist	Accelerometer	PD [63, 89, 96], dystonia [140], ataxia [134], MS [127]
1	Forearm	Inertial measurement unit	PD [72], stroke [117]
1/2 [66]†	Dorsal hand	Inertial measurement unit	PD [66, 68, 75, 84], ataxia [131], tremor [106, 109]
1/2 [78, 81, 82, 133, 137]†	Wrist(s)	Inertial measurement unit	PD [78, 81, 82, 100], stroke [15, 118, 122], CP [137], MS [123, 124, 126], ataxia [133], tremor [112]
1/2 [60]†	Wrist(s)	Gyroscope	PD [52, 60], tremor [108]
2	Hand and wrist	Inertial measurement unit & accelerometer	PD [86], ataxia [144]
2	Dorsal hand and index finger	Inertial measurement unit	PD [135]
2	Wrist and index finger	Accelerometer	PD [67, 142], tremor [111]
2	Thumb and index finger	Accelerometer	PD [54]
2	Thumb and index finger	Gyroscope	PD [64, 73]
2	Thumb and index finger	Inertial measurement unit	PD [58, 70, 71, 85, 88, 101]
3	Index finger, forearm, upper arm	Inertial measurement unit	Ataxia [132, 135]
3	Index finger, hand, forearm	Gyroscope	Tremor [105, 110]
3	Hand, forearm, upper arm	Inertial measurement unit	PD [74, 92], stroke [116], tremor [102]
3	Wrists and sternum	Accelerometer	HD [29]
3	Wrist, sternum and sacrum	Inertial measurement unit	Stroke [121]
3	Upper arms and trunk	Inertial measurement unit	CP [12]
4	Thumb, index finger, wrist, upper arm	Inertial measurement unit	Stroke [119]
4	Fingers and wrist	Inertial measurement unit	PD [83]
4	Hands and forearms	Inertial measurement unit	PD [76], tremor [103]
4	Wrists, trunk, head	Inertial measurement unit	PD [90]
4	Wrists and ankles	Inertial measurement unit	PD [77, 87], dyskinetic CP [139]
4	Wrist, sternum, thigh, foot	Inertial measurement unit	PD [57]
4	Hand, forearm, upper arm, shoulder	Inertial measurement unit	Spasticity [141]
5	Thumb, index finger, hand, wrist, upper arm	Magneto-inertial sensors	PD [80]
5	Hand, wrist, upper arm, shoulder, sternum	Inertial measurement unit	MS [125, 128]
5	Hand, forearm, upper arm, head, back	Orientation sensors	Dyskinetic CP [13]
6	Thumb, index finger, hand, forearm, upper arm, sternum	Accelerometer	Stroke [115, 120]
6	Hands, forearms, upper arms	Inertial measurement unit	PD [98], tremor [107]
6*	Dorsal hands, wrists, ankles	Inertial measurement unit	Ataxia [129]
6	Hand, scapula, thorax, sacrum, posterior of the head, lateral shank	Magnetic motion tracker	PD [55]
6	Wrists, waist, chest, ankles	Inertial measurement unit	PD [62]
7	Hands, wrists, upper arms, sternum	Inertial measurement unit	Stroke [28]
7	Wrists, upper arms, trunk, upper legs	Accelerometer	PD [47, 48]
8	Hands, wrists, upper arms, shoulder	Inertial measurement unit	Stroke [65]
8	Forearms, upper arms, sternum, thighs, right shin	Accelerometer	PD [49]
8	Forearms, upper arms, shins, upper legs	Accelerometer	PD [53, 56]
8	index finger, dorsal hand, wrist, dorsum foot, sternum, upper-back, ankles	Inertial measurement unit	Ataxia [136]
11	Dorsal hand and fingers	Inertial measurement unit	PD [11]
17	Hands, wrists, upper arms, clavicle's, sternum, head, pelvis, upper & lower legs, feet	Inertial measurement unit	PD [93]
Unknown	Upper limb (no specification)	Accelerometer	CP [138]

Table 1: Number, type and location of included sensors per reference. † Either 1 sensor was placed on the dorsal hand, or 1 on each hand. * Krishna et al. used one sensor but placed it subsequently on the L/R wrist, L/R dorsal hand and L/R ankle.

Time-domain	Formula/Feature description	Goal population
Execution time	$T_{m_i} = T_{t_i} - T_{0_i}$ [28]; Inter-tap-interval (ITI) [144]; mean, standard deviation, minimum, maximum, range, interquartile range, median, and tenth and ninetieth percentiles of time [133]; duration of sub movements [134]	Stroke [15, 28, 117], PD [11, 49, 54, 71, 75, 80], CP [12, 137], tremor [102, 144], MS [123, 124], ataxia [132, 134]
Movement Frequency	Number of rotations/movements [64]	PD [64, 83]
Mean acceleration & angular velocity	$m_i(k) = \frac{1}{2sf+1} \sum_{n=w(k)-sf}^{w(k)+sf} x_i(n)$ [62]; Mean absolute value ; Absolute & harmonic mean [139]	PD [62, 78, 86, 90], stroke [118], dyskinetic CP [139], ataxia [129]
STD acceleration & angular velocity	$s_i(k) = \sqrt{\frac{1}{2sf+1} \sum_{n=w(k)-sf}^{w(k)+sf} (x_i^f(n) - \bar{x}_i^f)^2}$ [62]; $\sigma(W) = \sqrt{\frac{1}{N} \sum_{i=1}^N (x_i - \mu(W))^2}$, $\mu(W) = mean$ [87]	PD [62, 78, 87]
MAX acceleration & angular velocity	Absolute max [75]	PD [75, 89], dyskinetic CP [139]
Timing of MAX acceleration & angular velocity	Absolute max [75]	PD [75]
RMS acceleration & angular velocity		PD [11, 86], dyskinetic CP [139], ataxia [129]
VAR acceleration & angular velocity		Stroke [118]; PD [86, 89], ataxia [129]
Mean acceleration	Mean acceleration in 2min epoch [63]	Stroke [115, 119, 120], PD [57, 63, 66, 96], HD [29], CP [137], tremor [111], ataxia [134]
STD acceleration		PD [54, 66, 89] HD [29], CP [137], tremor [104], ataxia [134]
MAX acceleration	Max acceleration in 2min epoch [63]; Moments of jerk magnitude [89]	PD [63, 89], CP [138], ataxia [133]
Mean angular velocity	Hand mobility [52]	PD [52, 64, 71, 74, 81, 83, 85], ataxia [132, 133]
STD angular velocity		PD [74], ataxia [133]
Median angular velocity		PD [82]
Median acceleration		PD [89]
MAX linear velocity	Average of maximum velocities [51]	PD [51, 54], stroke [115]
RMS acceleration		PD [53, 66, 89]; stroke [115, 116]
RMS angular velocity	Speed [69]; Mean Intensity (MI) = RMS angular velocity [108]	PD [50, 58-60, 69, 79, 88, 98, 99, 101], tremor [105, 108, 110]
Mean angular displacement		MS [128]
RMS angular displacement/movement amplitude	Amplitude [69]	PD [58-60, 69, 79, 83, 92, 93, 101], tremor [107, 110]
Range angular displacement	Hand activity [52]	PD [11, 52, 71, 82, 83, 90]
IQR angular displacement		PD [82]
Range acceleration		PD [53, 54, 89], stroke [122]
Range acceleration and angular velocity		PD [75, 76, 86]
Mean amplitude	Average amplitude [51]	PD [51, 64]
Range angular velocity	$RAV = \frac{1}{3} \sum_{frontal, vertical, lateral} range(\omega)$	PD [75, 80], CP [12, 137], ataxia [133]
IQR acceleration & angular velocity	Angular velocity [82]; angular acceleration [89]	PD [82, 89]
Range of jerk & angular acceleration	$(Acc/Gyr)_{ran} = \max(\dot{x}(t)) - \min(\dot{x}(t)) \cdot t \in \{1, W_n\}$ [72]	PD [72]
Peak-to-peak angular velocity	Difference between the mean of the highest and lowest 10 samples in W [87]	PD [73, 80, 87]
Magnitude angular velocity		PD [77]
Max, STD, RMS & min/max peak height		HD
Rotational jerk index	$rot_i = \log \sqrt{\frac{(T_{t_i} - T_{0_i})^3}{2\theta^p} \int_{T_{0_i}}^{T_{t_i}} \left\ \frac{d^2 \omega(t)}{dt^2} \right\ ^2 dt}$ [28]	Stroke [28]
Segment velocity	Square root of sum of squares of jerk signals in three directions [48]	PD [48]
Kurtosis	$S(W) = \frac{1/N \sum_{i=1}^N (x_i - \mu(W))^4}{\sigma(W)^4}$ [87]	PD [66, 76, 86, 87, 118], ataxia [134]
Skewness	$S(W) = \frac{1/N \sum_{i=1}^N (x_i - \mu(W))^3}{\sigma(W)^3}$ [87]	PD [66, 76, 78, 86, 87, 118]
Sample entropy	$H_i(k) = -\frac{1}{2sf+1} \sum_{n=w(k)-sf}^{w(k)+sf} p(x_i^f(n)) \log p(x_i^f(n))$ [62]	PD [53, 55, 62, 66, 70, 76, 86], HD [29], stroke [120], ataxia [136]
Approximate entropy	$H(W) = -\sum p(B_i) * \log p(B_i)$ [115]; Window length (m) = 2 and % STD (r) = 20% [78]	PD [49, 70, 78, 98, 118], stroke [115, 116]
Shannon entropy	Randomness in time domain: $H(W) = -\sum_{i=1}^{200} p(B_i) * \log p(B_i)$ [87]	PD [87], dyskinetic CP [139]
Permutation entropy	Assesses the complexity of the time series signal [29]	HD [29]
Fuzzy entropy		Ataxia [131, 144]
Gini index	Movement complexity in the time domain: $G(W) = 1 - \sum_{i=1}^{200} p(B_i)^2$ [87]	PD [87], ataxia [131]
Lyapunov exponent	Measures the level of chaos in a signal [29]	HD [29]
Recurrence rate (RR); Determinism	RR: Probability that any state will recur again; Determinism: Ratio of recurrence points	HD [29]
Average Diagonal line	Average time that signal segments remain the same [29]	HD [29]

Assessment of upper limb movement disorders

RMS of jerk		PD [118], stroke [115, 116]
Jerk metric	RM jerk normalized by peak velocity [115]; Moments of jerk magnitude [76, 89]; Logarithm of mean jerk amplitude, normalized to mean absolute acceleration movement duration [123]; Normalised Jerk Index: $NJI = \frac{1}{v_{peak}(t_1-t_2)} \int_{t_1}^{t_2} \left \frac{d^2v}{d\tau^2} \right dt$	Stroke [15, 115], PD [76, 89, 90], Multiple Sclerosis [123], CP [12], dyskinetic CP [13], spasticity [141]
Smoothness	Difference between movement accelerometer readings & smoothed readings [122]; Number of movement units [BAI]; number of speed peaks (NSP) [114]	Stroke [122], spasticity [141]
Coefficient of variation	Coefficient of variation of amplitude, speed & frequency [64, 71]; STD of a 1-second sliding window of the RMS excursion angle divided by the mean & Coefficient of variation of acceleration & angular velocity [58]; Coefficient of variation of excursion angle [58, 69, 79, 101]; Coefficient of variation of angular velocity [79]; Coefficient of variation of inter-tap - interval [144]	PD [58, 64, 69, 71, 79, 83, 101], tremor [144]
Rhythm	STD of intervals a single finger tap movement in 60 sec [51]; Any sequence of regularly recurring events [67];	PD [51, 67]
Variability	RMS error between the reference trial and the warped trial [117]	Stroke [117]
Higuchi's fractal dimension (HFD)	Geometrical structure of non-linear time series [12]	CP [12]
Correlation between axes	Mean, STD, skewness and kurtosis of signal derivative [86]; Correlation between each two axes of accelerometer [29]	PD [76, 86, 89, 99], HD [29], stroke [115]
Peak of normalized cross-correlation from pairs of acceleration time series		PD [53]
Lag of first peak in autocorrelation acceleration		PD [56]
Path length	Path-length-ratio (PLR) = distance travelled by hand/straight-line distance [114]; Length of 3D trajectories [121]; Index of curvature [13]; Mean & Standard deviation of Euclidian distance from the mean trajectory [132]; curved line similarity analysis, straight line similarity analysis [135]	Stroke [114, 121], dyskinetic CP [13], spasticity [141], ataxia [132]
Similarity of hand trajectories	$D_i = \sqrt{\frac{1}{s_{t_i}-s_{o_i}} \int_{s_{o_i}}^{s_{t_i}} \ p(\bar{s}) - p_r(\bar{s})\ ^2 d\bar{s}}$, $\hat{v}_i = \frac{1}{\pi} \sqrt{\frac{1}{s_{t_i}-s_{o_i}} \int_{s_{t_i}-s_{o_i}}^{s_{t_i}} v^2(\hat{s}) d\hat{s}}$, $X_i = \alpha D_i + \beta \hat{v}_i$ [28]	Stroke [28]
Elevation angle	$\theta = \max(\cos^{-1}(\frac{a_{vert(cal)}}{g}))$ [12]	CP [12]
Bradykinesia Index (BKI)	$BKI = \sqrt{\frac{STD+VEL}{Time_{var} * Amp_{var}}}$, var = STD of distances between signal peaks for time and amp [65]	PD [65]
Movement decrement	Slope of change in amplitude [71]; $\frac{\text{Amplitude in 2nd half time interval}}{\text{Amplitude in 1st half time interval}}$ [69]; Fatigability index: slope of linear equation fitted with peak-to-peak angular velocities [80]	PD [69, 71, 80]
Velocity decrement	Compare velocities between 1 st , 2 nd , 3 rd and 4 th part of the data [82]; $\frac{\text{Speed in 2nd half time interval}}{\text{Speed in 1st half time interval}}$ [69]	PD [69, 82]
Amplitude of modulation acceleration		PD [49]
Normalized mean squared error between a target signal and its forward linear prediction		PD [61]
Frequency-domain		
Dominant frequency component	Frequency associated with maximum power [87, 115]; Frequency in 1-4Hz and 4-8Hz bands [47]	PD [47, 53, 84, 87, 91, 94, 97-99, 104, 112, 126, 127, 129], stroke [115]
Second dominant frequency	Frequency associated with the second highest peak [87]	PD [87]
Dominant frequency of jerk		Stroke [115], ataxia [136]
Resonant Frequency (FR)	Peaks of FFT waveforms of angles and angular velocity [129]	Ataxia [129, 144]
Energy acceleration	Energy in 0.2Hz bin around dominant frequency [15, 115, 119, 120]	Stroke [115, 119, 120], PD [49, 53, 56, 66], HD [29]
Energy angular velocity		PD [100]
Energy acceleration & angular velocity	2-5Hz: $p_i^l(k) = \sum_{n=w(k)-sf}^{w(k)+sf} (x_i^l(n))^2$; 5-10Hz: $p_i^h(k) = \sum_{n=w(k)-sf}^{w(k)+sf} (x_i^h(n))^2$; [62]	Stroke [15], PD [62], ataxia [129]
Amplitude and dominant frequency of modulation associated with acceleration		PD [49]
Average magnitude of 1 st five STFT components		HD [29]
Fractal dimension acceleration		PD [49]
Spectral power	Frequency band 1.5-3Hz & 5-8Hz [118]; Frequency band dyskinesia: 0.3-3Hz [77]; Frequency band 0.5-15Hz & 1-4Hz [87]; Frequency band 0.6-16Hz [140]; Welch PSD of displacement; Power Spectral Density plots [68, 84]; PSD ratio 0.5-4Hz & 4-12Hz [102]; logarithm of the peak in the power spectrum in the tremor frequency band [113]	Stroke [118], PD [68, 77, 84, 87], dystonia [140], tremor [102, 113]
Peak power	Gyroscope; 0-4Hz frequency band [73]; Power of dominant frequency [87]; Position and amplitude of dominant peaks in power spectra of acceleration signals [104]	PD [59, 60, 73, 87, 99], tremor [102, 104, 105, 110], ataxia [134], MS [125]
Second peak power	Power of second dominant frequency [87]	PD [87]
Total power	Power spectrum of angular velocity [59]; Gyroscope; 0-4Hz frequency band [73]; power ratio ACC = (Power in 3-7Hz range)/(Power in 3-7Hz+Power in 7-12Hz) [96]	PD [59, 60, 73, 80, 96]

Mean power	0.2-4Hz frequency band [63]	PD [63]
Band power		Dyskinetic CP [139]
Spectral entropy		PD [62, 87], Ataxia [131]
Component entropy		HD [29]
Smoothness (Spectral Arc Length)	$SAL_{\pm} = - \int_0^{\Omega_c} \sqrt{\left(\frac{1}{\Omega}\right)^2 + \left(\frac{dV(\Omega)}{d\Omega}\right)^2} d\omega$, where $V(\Omega)_{\pm} = \frac{V(\Omega)}{V(0)}$ [12]	CP [12], PD [73, 80]
Specific tremor index	Tremor Index (TI) = 100*(rms[TR])/(rms[A]) with TR = tremor & A = norm of angular velocity [124]; Average Tremor amplitude (ATA) = 4 * LT _s Σ _{f=f₁} ^{f₂} √X(F) with L = # of frequency bins, T _s = sampling period, X = signal's PSD [128]; Mean logarithmic tremor power [103]; Tremor rotational amplitude & tremor amplitude based on identified peaks in power spectrum [106]	MS [124, 128], tremor [103, 106]
Tremor Frequency (TF) & Tremor Amplitude (TA)	TF= frequency distribution for highest maxima between 1-15Hz; TA = square root of integral of PSD +/- 1Hz of detected frequency [109]	Tremor [109]

674

Table 2: Calculated sensor features in time and frequency-domain. STD = standard deviation; max = maximal; RMS = root-mean-square; VAR = variance; IQR = inter-quartile range. PSD = power spectral density

Feature	articles (n)	articles reporting sensitivity (n)	articles reporting significant results (n)
RMS angular velocity	18	12	11
Mean acceleration	17	3	2
Execution time	17	10	10
Dominant frequency domain	15	1	1
Peak power	12	6	6
Sample entropy	11	2	2
RMS angular displacement/movement amplitude	11	10	9
Energy acceleration in frequency domain	11	0	0
STD acceleration	11	0	0
RMS acceleration	10	1	1
Mean angular velocity	10	6	6
Jerk metric	9	5	4
Coefficient of variation	8	5	5
Spectral power	7	4	3
Range acceleration	7	2	1
Approximate entropy	7	2	2
Range angular displacement	6	4	4
Mean acceleration & angular velocity	6	1	1
Correlation between axes	6	1	0
Skewness	6	0	0
Kurtosis	6	0	0

Table 3: Most prevalent features, the number of articles they appear in, the number of articles reporting sensitivity and the number of articles reporting significant results.

677

678 *Figure 1: Flowchart of article selection*

679

680 *Figure 2: Number of studies included per goal population*

681

682 *Figure 3: Overview of upper limbs tasks included in more than one study. The sum does not add up to 102 because*
683 *multiple studies used more than one task.*

684

Figure 4: Statistical method used in the included studies. The sum does not add up to 101 because multiple studies used more than one methodology.

687

688

689 *Figure 5: Clinical application. The sum does not add up to 101 because multiple studies*
690 *used more than one methodology.*

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707 **References**

- 708 1. Kukke, S.N., et al., *Coordination of Reach-to-Grasp Kinematics in Individuals With*
709 *Childhood-Onset Dystonia Due to Hemiplegic Cerebral Palsy*. IEEE Trans Neural Syst
710 Rehabil Eng, 2016. **24**(5): p. 582-590.
- 711 2. Levin, M.F., *Interjoint coordination during pointing movements is disrupted in spastic*
712 *hemiparesis*. Brain, 1996. **119**(1): p. 281-293.
- 713 3. Beer, R.F., J.P.A. Dewald, and W.Z. Rymer, *Deficits in the coordination of multijoint arm*
714 *movements in patients with hemiparesis: evidence for disturbed control of limb dynamics*.
715 Experimental Brain Research, 2000. **131**(3): p. 305-319.
- 716 4. Jankovic, J., et al., *Chapter 1 - Clinical overview and phenomenology of movement disorders,*
717 *in Principles and Practice of Movement Disorders (Third Edition)*, J. Jankovic, et al., Editors.
718 2021, Elsevier: London. p. 1-51.e27.
- 719 5. Wenning, G.K., et al., *Prevalence of movement disorders in men and women aged 50-89*
720 *years (Bruneck Study cohort): a population-based study*. Lancet Neurol, 2005. **4**(12): p. 815-
721 20.
- 722 6. Monbaliu, E., et al., *Clinical presentation and management of dyskinetic cerebral palsy*. The
723 Lancet Neurology, 2017. **16**(9): p. 741-749.
- 724 7. Nutt, J.G., et al., *Epidemiology of focal and generalized dystonia in Rochester, Minnesota*.
725 Mov Disord, 1988. **3**(3): p. 188-94.
- 726 8. Phukan, J., et al., *Primary dystonia and dystonia-plus syndromes: clinical characteristics,*
727 *diagnosis, and pathogenesis*. The Lancet Neurology, 2011. **10**(12): p. 1074-1085.
- 728 9. Müller, J., et al., *The prevalence of primary dystonia in the general community*. Neurology,
729 2002. **59**(6): p. 941-943.
- 730 10. Tysnes, O.B. and A. Storstein, *Epidemiology of Parkinson's disease*. J Neural Transm
731 (Vienna), 2017. **124**(8): p. 901-905.
- 732 11. van den Noort, J.C., et al., *Quantification of Hand Motor Symptoms in Parkinson's Disease: A*
733 *Proof-of-Principle Study Using Inertial and Force Sensors*. Ann Biomed Eng, 2017. **45**(10):
734 p. 2423-2436.
- 735 12. Newman, C.J., et al., *Measuring upper limb function in children with hemiparesis with 3D*
736 *inertial sensors*. Childs Nerv Syst, 2017. **33**(12): p. 2159-2168.
- 737 13. Sanger, T.D., *Arm trajectories in dyskinetic cerebral palsy have increased random*
738 *variability*. J Child Neurol, 2006. **21**(7): p. 551-7.
- 739 14. Lee, K.B., et al., *Six-month functional recovery of stroke patients: a multi-time-point study*.
740 International journal of rehabilitation research. Internationale Zeitschrift fur
741 Rehabilitationsforschung. Revue internationale de recherches de readaptation, 2015. **38**(2): p.
742 173-180.
- 743 15. Zhang, M., et al., *Beyond the standard clinical rating scales: fine-grained assessment of post-*
744 *stroke motor functionality using wearable inertial sensors*. Annu Int Conf IEEE Eng Med
745 Biol Soc, 2012. **2012**: p. 6111-5.
- 746 16. Cohen, N., et al., *Multidisciplinary intensive outpatient rehabilitation program for patients*
747 *with moderate-to-advanced Parkinson's disease*. NeuroRehabilitation, 2021. **49**(1): p. 47-55.

- 748 17. Jackman, M., et al., *Predicting Improvement in Writer's Cramp Symptoms following*
749 *Botulinum Neurotoxin Injection Therapy*. Tremor Other Hyperkinet Mov (N Y), 2016. **6**: p.
750 410.
- 751 18. Umar, M., T. Masood, and M. Badshah, *Effect of botulinum toxin A & task-specific training*
752 *on upper limb function in post-stroke focal dystonia*. J Pak Med Assoc, 2018. **68**(4): p. 526-
753 531.
- 754 19. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease, *The*
755 *Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations*.
756 *Movement Disorders*, 2003. **18**(7): p. 738-750.
- 757 20. Goetz, C.G., et al., *Movement Disorder Society-sponsored revision of the Unified Parkinson's*
758 *Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results*. Mov
759 *Disord*, 2008. **23**(15): p. 2129-70.
- 760 21. Hoehn, M.M. and M.D. Yahr, *Parkinsonism: onset, progression, and mortality*. 1967.
761 *Neurology*, 1998. **50**(2): p. 318 and 16 pages following.
- 762 22. disease, M.D.S.T.F.o.R.S.f.P.s., *Reliability of a new scale for essential tremor*. *Movement*
763 *disorders : official journal of the Movement Disorder Society*, 2012. **27**(12): p. 1567-1569.
- 764 23. Schmitz-Hübsch, T., et al., *Scale for the assessment and rating of ataxia: development of a*
765 *new clinical scale*. *Neurology*, 2006. **66**(11): p. 1717-20.
- 766 24. Fugl-Meyer, A.R., et al., *The post-stroke hemiplegic patient. 1. a method for evaluation of*
767 *physical performance*. *Scand J Rehabil Med*, 1975. **7**(1): p. 13-31.
- 768 25. Wolf, S.L., et al., *Assessing Wolf motor function test as outcome measure for research in*
769 *patients after stroke*. *Stroke*, 2001. **32**(7): p. 1635-9.
- 770 26. Gladstone, D.J., C.J. Danells, and S.E. Black, *The Fugl-Meyer Assessment of Motor Recovery*
771 *after Stroke: A Critical Review of Its Measurement Properties*. *Neurorehabilitation and*
772 *Neural Repair*, 2002. **16**(3): p. 232-240.
- 773 27. Platz, T., et al., *Reliability and validity of arm function assessment with standardized*
774 *guidelines for the Fugl-Meyer Test, Action Research Arm Test and Box and Block Test: a*
775 *multicentre study*. *Clin Rehabil*, 2005. **19**(4): p. 404-11.
- 776 28. Repnik, E., et al., *Using Inertial Measurement Units and Electromyography to Quantify*
777 *Movement during Action Research Arm Test Execution*. *Sensors (Basel)*, 2018. **18**(9).
- 778 29. Bennasar, M., et al., *Automated Assessment of Movement Impairment in Huntington's*
779 *Disease*. *IEEE Trans Neural Syst Rehabil Eng*, 2018. **26**(10): p. 2062-2069.
- 780 30. Gilmore, R., L. Sakzewski, and R. Boyd, *Upper limb activity measures for 5- to 16-year-old*
781 *children with congenital hemiplegia: a systematic review*. *Dev Med Child Neurol*, 2010.
782 **52**(1): p. 14-21.
- 783 31. Spirtos, M., P. O'Mahony, and J. Malone, *Interrater reliability of the Melbourne Assessment*
784 *of Unilateral Upper Limb Function for children with hemiplegic cerebral palsy*. *Am J Occup*
785 *Ther*, 2011. **65**(4): p. 378-83.
- 786 32. Burke, R.E., et al., *Validity and reliability of a rating scale for the primary torsion dystonias*.
787 *Neurology*, 1985. **35**(1): p. 73-7.

- 788 33. Monbaliu, E., et al., *The Dyskinesia Impairment Scale: a new instrument to measure dystonia*
789 *and choreoathetosis in dyskinetic cerebral palsy*. *Developmental Medicine & Child*
790 *Neurology*, 2012. **54**(3): p. 278-283.
- 791 34. Pang, Y., et al., *Automatic detection and quantification of hand movements toward*
792 *development of an objective assessment of tremor and bradykinesia in Parkinson's disease*.
793 *Journal of Neuroscience Methods*, 2020. **333**: p. 108576.
- 794 35. Agostino, R., et al., *Impairment of individual finger movements in Parkinson's disease*.
795 *Movement Disorders*, 2003. **18**(5): p. 560-565.
- 796 36. Kreulen, M., et al., *Movement patterns of the upper extremity and trunk before and after*
797 *corrective surgery of impaired forearm rotation in patients with cerebral palsy*. *Dev Med*
798 *Child Neurol*, 2006. **48**(6): p. 436-41.
- 799 37. Butler, E.E. and J. Rose, *The pediatric upper limb motion index and a temporal-spatial*
800 *logistic regression: quantitative analysis of upper limb movement disorders during the Reach*
801 *& Grasp Cycle*. *J Biomech*, 2012. **45**(6): p. 945-51.
- 802 38. Simon-Martinez, C., et al., *Effects of combining constraint-induced movement therapy and*
803 *action-observation training on upper limb kinematics in children with unilateral cerebral*
804 *palsy: a randomized controlled trial*. *Scientific Reports*, 2020. **10**(1): p. 10421.
- 805 39. Cuesta-Gómez, A., et al., *Functional electrical stimulation improves reaching movement in*
806 *the shoulder and elbow muscles of stroke patients: A three-dimensional motion analysis*.
807 *Restor Neurol Neurosci*, 2019. **37**(3): p. 231-238.
- 808 40. Alt Murphy, M., et al., *Kinematic Analysis Using 3D Motion Capture of Drinking Task in*
809 *People With and Without Upper-extremity Impairments*. *J Vis Exp*, 2018(133).
- 810 41. Lang, C.E., S.L. DeJong, and J.A. Beebe, *Recovery of thumb and finger extension and its*
811 *relation to grasp performance after stroke*. *J Neurophysiol*, 2009. **102**(1): p. 451-9.
- 812 42. Maetzler, W., et al., *Quantitative wearable sensors for objective assessment of Parkinson's*
813 *disease*. *Mov Disord*, 2013. **28**(12): p. 1628-37.
- 814 43. Tortelli, R., F.B. Rodrigues, and E.J. Wild, *The use of wearable/portable digital sensors in*
815 *Huntington's disease: A systematic review*. *Parkinsonism & Related Disorders*, 2021. **83**: p.
816 93-104.
- 817 44. Haberfehlner, H., et al., *Instrumented assessment of motor function in dyskinetic cerebral*
818 *palsy: a systematic review*. *Journal of NeuroEngineering and Rehabilitation*, 2020. **17**(1): p.
819 39.
- 820 45. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic*
821 *reviews*. *BMJ*, 2021. **372**: p. n71.
- 822 46. Morgan, R.L., et al., *Identifying the PECO: A framework for formulating good questions to*
823 *explore the association of environmental and other exposures with health outcomes*.
824 *Environment international*, 2018. **121**(Pt 1): p. 1027-1031.
- 825 47. Hoff, J.I., et al., *Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's*
826 *disease*. *Mov Disord*, 2001. **16**(1): p. 58-61.
- 827 48. Keijsers, N.L., M.W. Horstink, and S.C. Gielen, *Automatic assessment of levodopa-induced*
828 *dyskinesias in daily life by neural networks*. *Mov Disord*, 2003. **18**(1): p. 70-80.

- 829 49. Bonato, P., et al., *Data mining techniques to detect motor fluctuations in Parkinson's disease*.
830 Conf Proc IEEE Eng Med Biol Soc, 2004. **2004**: p. 4766-9.
- 831 50. Koop, M.M., et al., *Improvement in a quantitative measure of bradykinesia after*
832 *microelectrode recording in patients with Parkinson's disease during deep brain stimulation*
833 *surgery*. Movement Disorders, 2006. **21**(5): p. 673-678.
- 834 51. Okuno, R., et al., *Finger taps movement acceleration measurement system for quantitative*
835 *diagnosis of Parkinson's disease*. Conf Proc IEEE Eng Med Biol Soc, 2006. **Suppl**: p. 6623-
836 6.
- 837 52. Salarian, A., et al., *Quantification of tremor and bradykinesia in Parkinson's disease using a*
838 *novel ambulatory monitoring system*. IEEE Trans Biomed Eng, 2007. **54**(2): p. 313-22.
- 839 53. Patel, S., et al., *Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using*
840 *Wearable Sensors*. IEEE Transactions on Information Technology in Biomedicine, 2009.
841 **13**(6): p. 864-873.
- 842 54. Yokoe, M., et al., *Opening velocity, a novel parameter, for finger tapping test in patients with*
843 *Parkinson's disease*. Parkinsonism Relat Disord, 2009. **15**(6): p. 440-4.
- 844 55. Chelaru, M.I., C. Duval, and M. Jog, *Levodopa-induced dyskinesias detection based on the*
845 *complexity of involuntary movements*. Journal of Neuroscience Methods, 2010. **186**(1): p. 81-
846 89.
- 847 56. Cole, B.T., et al., *Dynamic neural network detection of tremor and dyskinesia from wearable*
848 *sensor data*. Annu Int Conf IEEE Eng Med Biol Soc, 2010. **2010**: p. 6062-5.
- 849 57. Zwartjes, D.G., et al., *Ambulatory monitoring of activities and motor symptoms in*
850 *Parkinson's disease*. IEEE Trans Biomed Eng, 2010. **57**(11).
- 851 58. Espay, A.J., et al., *Differential response of speed, amplitude, and rhythm to dopaminergic*
852 *medications in Parkinson's disease*. Mov Disord, 2011. **26**(14): p. 2504-8.
- 853 59. Kim, J.W., et al., *Quantification of bradykinesia during clinical finger taps using a*
854 *gyrosensor in patients with Parkinson's disease*. Med Biol Eng Comput, 2011. **49**(3): p. 365-
855 71.
- 856 60. Jun, J.-H., et al., *Quantification of limb bradykinesia in patients with Parkinson's disease*
857 *using a gyrosensor — Improvement and validation*. International Journal of Precision
858 Engineering and Manufacturing, 2011. **12**(3): p. 557-563.
- 859 61. Hoffman, J.D. and J. McNames, *Objective measure of upper extremity motor impairment in*
860 *Parkinson's disease with inertial sensors*. Conf Proc IEEE Eng Med Biol Soc, 2011. **2011**: p.
861 4378-81.
- 862 62. Tsiouras, M.G., et al., *An automated methodology for levodopa-induced dyskinesia:*
863 *assessment based on gyroscope and accelerometer signals*. Artif Intell Med, 2012. **55**(2): p.
864 127-35.
- 865 63. Griffiths, R.I., et al., *Automated assessment of bradykinesia and dyskinesia in Parkinson's*
866 *disease*. J Parkinsons Dis, 2012. **2**(1): p. 47-55.
- 867 64. Lee, M.J., et al., *Impact of regional striatal dopaminergic function on kinematic parameters*
868 *of Parkinson's disease*. J Neural Transm (Vienna), 2015. **122**(5): p. 669-77.
- 869 65. Delrobaei, M., et al., *Characterization of multi-joint upper limb movements in a single task to*
870 *assess bradykinesia*. J Neurol Sci, 2016. **368**: p. 337-42.

- 871 66. Ghassemi, N.H., et al., *Combined accelerometer and EMG analysis to differentiate essential*
872 *tremor from Parkinson's disease*. Conf Proc IEEE Eng Med Biol Soc, 2016. **2016**: p. 672-
873 675.
- 874 67. Martinez-Manzanera, O., et al., *A Method for Automatic and Objective Scoring of*
875 *Bradykinesia Using Orientation Sensors and Classification Algorithms*. IEEE Trans Biomed
876 Eng, 2016. **63**(5): p. 1016-1024.
- 877 68. Bravo, M., et al. *An upper-limbs activities analysis of PD patients in OFF and ON state of*
878 *medication*. in *2016 IEEE Ecuador Technical Chapters Meeting (ETCM)*. 2016.
- 879 69. Tamás, G., et al., *Effect of subthalamic stimulation on distal and proximal upper limb*
880 *movements in Parkinson's disease*. Brain Res, 2016. **1648**(Pt A): p. 438-444.
- 881 70. Liu, Y., et al., *[Quantitative Evaluation of Regularity of Finger Tapping Movement for*
882 *Patients with Parkinson's disease]*. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2016. **33**(5):
883 p. 979-84.
- 884 71. Djurić-Jovičić, M., et al., *Finger tapping analysis in patients with Parkinson's disease and*
885 *atypical parkinsonism*. J Clin Neurosci, 2016. **30**: p. 49-55.
- 886 72. Spasojević, S., et al., *Quantitative Assessment of the Arm/Hand Movements in Parkinson's*
887 *Disease Using a Wireless Armband Device*. Front Neurol, 2017. **8**.
- 888 73. Summa, S., et al., *Assessing bradykinesia in Parkinson's disease using gyroscope signals*.
889 IEEE Int Conf Rehabil Robot, 2017. **2017**: p. 1556-1561.
- 890 74. Angeles, P., et al., *Automated assessment of symptom severity changes during deep brain*
891 *stimulation (DBS) therapy for Parkinson's disease*. IEEE Int Conf Rehabil Robot, 2017.
892 **2017**: p. 1512-1517.
- 893 75. Rabelo, A.G., et al., *Objective Assessment of Bradykinesia Estimated from the Wrist*
894 *Extension in Older Adults and Patients with Parkinson's Disease*. Ann Biomed Eng, 2017.
895 **45**(11): p. 2614-2625.
- 896 76. Lonini, L., et al., *Wearable sensors for Parkinson's disease: which data are worth collecting*
897 *for training symptom detection models*. npj Digital Medicine, 2018. **1**(1): p. 64.
- 898 77. Pulliam, C.L., et al., *Continuous Assessment of Levodopa Response in Parkinson's Disease*
899 *Using Wearable Motion Sensors*. IEEE Trans Biomed Eng, 2018. **65**(1): p. 159-164.
- 900 78. Thomas, I., et al., *A Treatment-Response Index From Wearable Sensors for Quantifying*
901 *Parkinson's Disease Motor States*. IEEE Journal of Biomedical and Health Informatics, 2018.
902 **22**(5): p. 1341-1349.
- 903 79. Kwon, D.-Y., Y. Kwon, and J.-W. Kim, *Quantitative analysis of finger and forearm*
904 *movements in patients with off state early stage Parkinson's disease and scans without*
905 *evidence of dopaminergic deficit (SWEDD)*. Parkinsonism & Related Disorders, 2018. **57**: p.
906 33-38.
- 907 80. di Biase, L., et al., *Quantitative Analysis of Bradykinesia and Rigidity in Parkinson's Disease*.
908 Front Neurol, 2018. **9**: p. 121.
- 909 81. Garza-Rodríguez, A., et al., *Pronation and supination analysis based on biomechanical*
910 *signals from Parkinson's disease patients*. Artif Intell Med, 2018. **84**: p. 7-22.

- 911 82. Garza-Rodríguez, A., et al., *Fuzzy inference model based on triaxial signals for pronation*
 912 *and supination assessment in Parkinson's disease patients*. Artificial Intelligence in
 913 Medicine, 2020. **105**: p. 101873.
- 914 83. Cavallo, F., et al., *Upper limb motor pre-clinical assessment in Parkinson's disease using*
 915 *machine learning*. Parkinsonism Relat Disord, 2019. **63**: p. 111-116.
- 916 84. Bermeo, J., et al., *Artificial Neural Network Applied like Qualifier of Symptoms in Patients*
 917 *with Parkinson's Disease by Evaluating the Movement of Upper-Limbs Activities*. 2019. p.
 918 409-414.
- 919 85. Li, J., et al., *Three-Dimensional Pattern Features in Finger Tapping Test for Patients with*
 920 *Parkinson's disease*. Annu Int Conf IEEE Eng Med Biol Soc, 2020. **2020**: p. 3676-3679.
- 921 86. Shawen, N., et al., *Role of data measurement characteristics in the accurate detection of*
 922 *Parkinson's disease symptoms using wearable sensors*. Journal of NeuroEngineering and
 923 Rehabilitation, 2020. **17**(1): p. 52.
- 924 87. Hssayeni, M.D., et al., *Dyskinesia estimation during activities of daily living using wearable*
 925 *motion sensors and deep recurrent networks*. Scientific Reports, 2021. **11**(1): p. 7865.
- 926 88. Park, D.J., et al., *Evaluation for Parkinsonian Bradykinesia by deep learning modeling of*
 927 *kinematic parameters*. J Neural Transm (Vienna), 2021. **128**(2): p. 181-189.
- 928 89. Habets, J.G.V., et al., *Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's*
 929 *Disease Using a Wrist-Worn Accelerometer*. Sensors (Basel), 2021. **21**(23).
- 930 90. Romano, P., et al., *Sensor Network for Analyzing Upper Body Strategies in Parkinson's*
 931 *Disease versus Normative Kinematic Patterns*. Sensors (Basel), 2021. **21**(11).
- 932 91. Bravo, M., et al. *A system for finger tremor quantification in patients with Parkinson's*
 933 *disease*. in *2017 39th Annual International Conference of the IEEE Engineering in Medicine*
 934 *and Biology Society (EMBC)*. 2017.
- 935 92. Chan, P.Y., et al., *Motion characteristics of subclinical tremors in Parkinson's disease and*
 936 *normal subjects*. Scientific Reports, 2022. **12**(1): p. 4021.
- 937 93. Delrobaei, M., et al., *Towards remote monitoring of Parkinson's disease tremor using*
 938 *wearable motion capture systems*. J Neurol Sci, 2018. **384**: p. 38-45.
- 939 94. Makabe, H. and K. Sakamoto, *Judgment of disability stages in Parkinson disease patients due*
 940 *to pathological tremor of index finger*. Electromyogr Clin Neurophysiol, 2000. **40**(7): p. 397-
 941 409.
- 942 95. Rahimi, F., et al., *Effective Management of Upper Limb Parkinsonian Tremor by*
 943 *IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns*. Tremor Other
 944 Hyperkinet Mov (N Y), 2015. **5**: p. 348.
- 945 96. Schaefer, L.V., et al., *Mechanomyography and acceleration show interlimb asymmetries in*
 946 *Parkinson patients without tremor compared to controls during a unilateral motor task*.
 947 Scientific Reports, 2021. **11**(1): p. 2631.
- 948 97. Thanawattano, C., et al., *Temporal fluctuation analysis of tremor signal in Parkinson's*
 949 *disease and Essential tremor subjects*. Annu Int Conf IEEE Eng Med Biol Soc, 2015. **2015**:
 950 p. 6054-7.

- 951 98. Lukšys, D., G. Jonaitis, and J. Griškevičius, *Quantitative Analysis of Parkinsonian Tremor in*
952 *a Clinical Setting Using Inertial Measurement Units*. Parkinson's Disease, 2018.
953 **2018**: p. 1683831.
- 954 99. Zhu, N. and N.S. Miller, *Assessment System for Parkinson's Disease Tremor and Correlation*
955 *Analysis With Applied Signal Processing Algorithms*. Journal of Engineering and Science in
956 Medical Diagnostics and Therapy, 2020. **3**(4).
- 957 100. Rigas, G., et al., *Tremor UPDRS estimation in home environment*. Annu Int Conf IEEE Eng
958 Med Biol Soc, 2016. **2016**: p. 3642-3645.
- 959 101. Heldman, D.A., et al., *The modified bradykinesia rating scale for Parkinson's disease:*
960 *reliability and comparison with kinematic measures*. Mov Disord, 2011. **26**(10): p. 1859-63.
- 961 102. Ali, S.M., et al., *Wearable sensors during drawing tasks to measure the severity of essential*
962 *tremor*. Scientific Reports, 2022. **12**(1): p. 5242.
- 963 103. Benito-León, J., et al., *Essential tremor severity and anatomical changes in brain areas*
964 *controlling movement sequencing*. Ann Clin Transl Neurol, 2019. **6**(1): p. 83-97.
- 965 104. Budini, F., et al., *Dexterity training improves manual precision in patients affected by*
966 *essential tremor*. Arch Phys Med Rehabil, 2014. **95**(4): p. 705-10.
- 967 105. Heo, J.H., et al., *Sensory electrical stimulation for suppression of postural tremor in patients*
968 *with essential tremor*. Biomed Mater Eng, 2015. **26 Suppl 1**: p. S803-9.
- 969 106. McGurrin, P., et al., *Quantifying Tremor in Essential Tremor Using Inertial Sensors-*
970 *Validation of an Algorithm*. IEEE J Transl Eng Health Med, 2021. **9**: p. 2700110.
- 971 107. Chan, P.Y., et al., *An In-Laboratory Validity and Reliability Tested System for Quantifying*
972 *Hand-Arm Tremor in Motions*. IEEE Transactions on Neural Systems and Rehabilitation
973 Engineering, 2018. **26**(2): p. 460-467.
- 974 108. López-Blanco, R., et al., *Essential tremor quantification based on the combined use of a*
975 *smartphone and a smartwatch: The NetMD study*. Journal of Neuroscience Methods, 2018.
976 **303**: p. 95-102.
- 977 109. Šprdlík, O., et al., *Tremor analysis by decomposition of acceleration into gravity and inertial*
978 *acceleration using inertial measurement unit*. Biomedical Signal Processing and Control,
979 2011. **6**(3): p. 269-279.
- 980 110. Kwon, D.Y., et al., *Quantitative measures of postural tremor at the upper limb joints in*
981 *patients with essential tremor*. Technol Health Care, 2020. **28**(S1): p. 499-507.
- 982 111. Samotus, O., et al., *Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA*
983 *Injections Using Kinematically Determined Biomechanical Patterns – A New Future*. PLOS
984 ONE, 2016. **11**(4): p. e0153739.
- 985 112. Gallego, J., et al., *A Multimodal Human-Robot Interface to Drive a Neuroprosthesis for*
986 *Tremor Management*. Systems, Man, and Cybernetics, Part C: Applications and Reviews,
987 IEEE Transactions on, 2012. **42**: p. 1159-1168.
- 988 113. Heldman, D.A., et al., *Essential tremor quantification during activities of daily living*.
989 Parkinsonism & related disorders, 2011. **17**(7): p. 537-542.
- 990 114. Kamper, D.G., et al., *Alterations in reaching after stroke and their relation to movement*
991 *direction and impairment severity*. Arch Phys Med Rehabil, 2002. **83**(5): p. 702-7.

- 992 115. Hester, T., et al. *Using wearable sensors to measure motor abilities following stroke*. in
993 *International Workshop on Wearable and Implantable Body Sensor Networks (BSN'06)*.
994 2006.
- 995 116. Knorr, B., et al. *Quantitative Measures of Functional Upper Limb Movement in Persons after*
996 *Stroke*. in *Conference Proceedings. 2nd International IEEE EMBS Conference on Neural*
997 *Engineering, 2005*. 2005.
- 998 117. Thies, S.B., et al., *Movement variability in stroke patients and controls performing two upper*
999 *limb functional tasks: a new assessment methodology*. *J Neuroeng Rehabil*, 2009. **6**: p. 2.
- 1000 118. Parnandi, A., E. Wade, and M. Mataric, *Motor function assessment using wearable inertial*
1001 *sensors*. *Conf Proc IEEE Eng Med Biol Soc*, 2010. **2010**: p. 86-9.
- 1002 119. Del Din, S., et al., *Estimating Fugl-Meyer clinical scores in stroke survivors using wearable*
1003 *sensors*. *Annu Int Conf IEEE Eng Med Biol Soc*, 2011. **2011**: p. 5839-42.
- 1004 120. Patel, S., et al., *Tracking motor recovery in stroke survivors undergoing rehabilitation using*
1005 *wearable technology*. *Annu Int Conf IEEE Eng Med Biol Soc*, 2010. **2010**: p. 6858-61.
- 1006 121. van Meulen, F.B., et al., *Assessment of daily-life reaching performance after stroke*. *Ann*
1007 *Biomed Eng*, 2015. **43**(2): p. 478-86.
- 1008 122. Otten, P., J. Kim, and S.H. Son, *A Framework to Automate Assessment of Upper-Limb Motor*
1009 *Function Impairment: A Feasibility Study*. *Sensors*, 2015. **15**(8): p. 20097-20114.
- 1010 123. Carpinella, I., D. Cattaneo, and M. Ferrarin, *Quantitative assessment of upper limb motor*
1011 *function in Multiple Sclerosis using an instrumented Action Research Arm Test*. *J Neuroeng*
1012 *Rehabil*, 2014. **11**: p. 67.
- 1013 124. Carpinella, I., D. Cattaneo, and M. Ferrarin, *Hilbert-Huang transform based instrumental*
1014 *assessment of intention tremor in multiple sclerosis*. *J Neural Eng*, 2015. **12**(4): p. 046011.
- 1015 125. Ketteringham, L.P., et al. *Measuring Intention Tremor in Multiple Sclerosis using Inertial*
1016 *Measurement Unit (IMU) Devices*. in *BIODEVICES*. 2011.
- 1017 126. Teufl, S., et al., *Quantifying upper limb tremor in people with multiple sclerosis using Fast*
1018 *Fourier Transform based analysis of wrist accelerometer signals*. *J Rehabil Assist Technol*
1019 *Eng*, 2021. **8**: p. 2055668320966955.
- 1020 127. Teufl, S., et al., *Objective identification of upper limb tremor in multiple sclerosis using a*
1021 *wrist-worn motion sensor: Establishing validity and reliability*. *British Journal of*
1022 *Occupational Therapy*, 2017. **80**(10): p. 596-602.
- 1023 128. Western, D.G., et al., *Personalised profiling to identify clinically relevant changes in tremor*
1024 *due to multiple sclerosis*. *BMC Medical Informatics and Decision Making*, 2019. **19**(1): p.
1025 162.
- 1026 129. Krishna, R., et al., *Quantitative assessment of cerebellar ataxia, through automated limb*
1027 *functional tests*. *Journal of NeuroEngineering and Rehabilitation*, 2019. **16**(1): p. 31.
- 1028 130. Uswatte, G., et al., *Objective measurement of functional upper-extremity movement using*
1029 *accelerometer recordings transformed with a threshold filter*. *Stroke*, 2000. **31**(3): p. 662-7.
- 1030 131. Nguyen, K.D., et al., *Entropy-based analysis of rhythmic tapping for the quantitative*
1031 *assessment of cerebellar ataxia*. *Biomedical Signal Processing and Control*, 2020. **59**: p.
1032 101916.


- 1033 132. Dominguez-Vega, Z.T., et al., *Instrumented classification of patients with early onset ataxia*
 1034 *or developmental coordination disorder and healthy control children combining information*
 1035 *from three upper limb SARA tests*. European Journal of Paediatric Neurology, 2021. **34**: p. 74-
 1036 83.
- 1037 133. Oubre, B., et al., *Decomposition of Reaching Movements Enables Detection and*
 1038 *Measurement of Ataxia*. Cerebellum, 2021. **20**(6): p. 811-822.
- 1039 134. Gupta, A.S., et al., *Real-life Wrist Movement Patterns Capture Motor Impairment in*
 1040 *Individuals with Ataxia-Telangiectasia*. Cerebellum, 2022: p. 1-11.
- 1041 135. Martinez-Manzanera, O., et al., *Instrumented finger-to-nose test classification in children*
 1042 *with ataxia or developmental coordination disorder and controls*. Clin Biomech (Bristol,
 1043 Avon), 2018. **60**: p. 51-59.
- 1044 136. Kashyap, B., et al., *Objective Assessment of Cerebellar Ataxia: A Comprehensive and Refined*
 1045 *Approach*. Scientific Reports, 2020. **10**(1): p. 9493.
- 1046 137. Strohrmann, C., et al., *Monitoring motor capacity changes of children during rehabilitation*
 1047 *using body-worn sensors*. Journal of NeuroEngineering and Rehabilitation, 2013. **10**(1): p. 83.
- 1048 138. Kim, D.H., D.H. An, and W.G. Yoo, *Measurement of upper limb movement acceleration and*
 1049 *functions in children with cerebral palsy*. Technol Health Care, 2018. **26**(3): p. 429-435.
- 1050 139. den Hartog, D., et al., *Home-Based Measurements of Dystonia in Cerebral Palsy Using*
 1051 *Smartphone-Coupled Inertial Sensor Technology and Machine Learning: A Proof-of-Concept*
 1052 *Study*. Sensors, 2022. **22**(12): p. 4386.
- 1053 140. Legros, A., et al., *Accelerometric measurement of involuntary movements during pallidal*
 1054 *deep brain stimulation of patients with generalized dystonia*. Brain Res Bull, 2004. **64**(4): p.
 1055 363-9.
- 1056 141. Bai, L., et al., *Quantitative measurement of upper limb motion pre- and post-treatment with*
 1057 *Botulinum Toxin*. Measurement, 2021. **168**: p. 108304.
- 1058 142. Rahimi, F., et al., *Capturing whole-body mobility of patients with Parkinson disease using*
 1059 *inertial motion sensors: expected challenges and rewards*. Conf Proc IEEE Eng Med Biol
 1060 Soc, 2011. **2011**: p. 5833-8.
- 1061 143. Ghassemi, M., et al., *Bradykinesia in patients with Parkinson's disease having levodopa-*
 1062 *induced dyskinesias*. Brain Res Bull, 2006. **69**(5): p. 512-8.
- 1063 144. Tran, H., et al., *A comprehensive scheme for the objective upper body assessments of subjects*
 1064 *with cerebellar ataxia*. J Neuroeng Rehabil, 2020. **17**(1): p. 162.
- 1065 145. Patel, S., et al., *Using wearable sensors to predict the severity of symptoms and motor*
 1066 *complications in late stage Parkinson's Disease*. Conf Proc IEEE Eng Med Biol Soc, 2008.
 1067 **2008**: p. 3686-9.
- 1068 146. Liu, X., et al., *Quantifying drug-induced dyskinesias in the arms using digitised spiral-*
 1069 *drawing tasks*. J Neurosci Methods, 2005. **144**(1): p. 47-52.
- 1070 147. Feigin, V.L., et al., *World Stroke Organization (WSO): Global Stroke Fact Sheet 2022*.
 1071 International Journal of Stroke, 2022. **17**(1): p. 18-29.
- 1072 148. Song, P., et al., *The global prevalence of essential tremor, with emphasis on age and sex: A*
 1073 *meta-analysis*. Journal of global health, 2021. **11**: p. 04028-04028.

- 1074 149. McIntyre, S., et al., *Cerebral palsy--don't delay*. Dev Disabil Res Rev, 2011. **17**(2): p. 114-29.
- 1075 150. Marras, C., et al., *Prevalence of Parkinson's disease across North America*. npj Parkinson's
1076 Disease, 2018. **4**(1): p. 21.
- 1077 151. Okubadejo, N.U., et al., *Parkinson's disease in Africa: A systematic review of epidemiologic
1078 and genetic studies*. Mov Disord, 2006. **21**(12): p. 2150-6.
- 1079 152. Van Den Eeden, S.K., et al., *Incidence of Parkinson's disease: variation by age, gender, and
1080 race/ethnicity*. Am J Epidemiol, 2003. **157**(11): p. 1015-22.
- 1081 153. Musselman, K.E., et al., *Prevalence of ataxia in children: a systematic review*. Neurology,
1082 2014. **82**(1): p. 80-89.
- 1083 154. Ruano, L., et al., *The Global Epidemiology of Hereditary Ataxia and Spastic Paraplegia: A
1084 Systematic Review of Prevalence Studies*. Neuroepidemiology, 2014. **42**(3): p. 174-183.
- 1085 155. Medina, A., et al., *Prevalence and Incidence of Huntington's Disease: An Updated Systematic
1086 Review and Meta-Analysis*. Movement Disorders. **n/a**(n/a).
- 1087 156. Crowell, V., et al., *Modeling Manifest Huntington's Disease Prevalence Using Diagnosed
1088 Incidence and Survival Time*. Neuroepidemiology, 2021. **55**(5): p. 361-368.
- 1089 157. Del Din, S., et al., *Body-Worn Sensors for Remote Monitoring of Parkinson's Disease Motor
1090 Symptoms: Vision, State of the Art, and Challenges Ahead*. Journal of Parkinson's Disease,
1091 2021. **11**: p. S35-S47.
- 1092 158. Jankovic, J., *Motor fluctuations and dyskinesias in Parkinson's disease: clinical
1093 manifestations*. Mov Disord, 2005. **20 Suppl 11**: p. S11-6.
- 1094 159. Serrano, J.I., et al., *Identification of activities of daily living in tremorous patients using
1095 inertial sensors*. Expert Systems with Applications, 2017. **83**: p. 40-48.
- 1096 160. Nguyen, H., et al., *Auto detection and segmentation of daily living activities during a Timed
1097 Up and Go task in people with Parkinson's disease using multiple inertial sensors*. J
1098 Neuroeng Rehabil, 2017. **14**(1): p. 26.
- 1099 161. Pham, M.H., et al., *Algorithm for Turning Detection and Analysis Validated under Home-Like
1100 Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-
1101 Freedom Inertial Measurement Unit at the Lower Back*. Front Neurol, 2017. **8**: p. 135.
- 1102 162. Beani, E., et al., *Actigraph assessment for measuring upper limb activity in unilateral
1103 cerebral palsy*. J Neuroeng Rehabil, 2019. **16**(1): p. 30.
- 1104 163. Ahmadi, M.N., et al., *Machine Learning to Quantify Physical Activity in Children with
1105 Cerebral Palsy: Comparison of Group, Group-Personalized, and Fully-Personalized Activity
1106 Classification Models*. Sensors (Basel), 2020. **20**(14).
- 1107 164. Braito, I., et al., *Assessment of upper limb use in children with typical development and
1108 neurodevelopmental disorders by inertial sensors: a systematic review*. J Neuroeng Rehabil,
1109 2018. **15**(1): p. 94.
- 1110 165. Biswas, D., et al., *Recognizing upper limb movements with wrist worn inertial sensors using
1111 k-means clustering classification*. Hum Mov Sci, 2015. **40**: p. 59-76.


1112

1113


Clinical application




Statistical method used



Upper limb tasks



Number of studies included per goal population



Identification of studies via databases and registers

Identification of new studies via other methods

Identification

Records identified from:
Databases (n=990)
Web Of Science: 197
Scopus: 517
PubMed: 276

Registers (n=0)

Records removed before
screening:
Duplicate records removed
(n=87)

Records identified from:
Citation searching (n=39)

Screening

Records screened for title
and abstract
(n=903)

Records excluded based on title
and abstract
(n=737)

Reports sought for
retrieval
(n=166)

Reports not retrieved
(n=0)

Reports sought for
retrieval
(n=39)

Reports assessed for
eligibility
(n = 166)

Reports excluded (n=104)
No movement disorders: 17
No wearable sensors/Glove: 46
No feature description: 17
No upper limb tasks: 6
Exact same feature as included
study: 4
Only range of motion/activity: 13
Sensor location not mentioned: 1

Reports assessed for
eligibility
(n=39)

Included

Studies included via
Searches
(n=62)
Citation searching
(n=39)
Studies included in review
(n=101)

